ANGELALIGN TECHNOLOGY INC.
時代天使科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 6699)

INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS PERIOD ENDED JUNE 30, 2025

The board (the "**Board**") of directors (the "**Directors**") of Angelalign Technology Inc. (the "**Company**", together with its subsidiaries, the "**Group**") is pleased to announce the unaudited consolidated interim results of the Group for the six months period ended June 30, 2025 (the "**Reporting Period**"), together with the comparative figures for the six months period ended June 30, 2024, which have been reviewed by the audit committee of the Board (the "**Audit Committee**").

In this announcement, "we", "us", "our" and "Angel" refer to the Company and where the context otherwise requires, the Group. Unless the context requires otherwise, capitalized terms used herein shall have the same meanings as those defined in the prospectus of the Company dated June 3, 2021 (the "**Prospectus**").

RESULTS HIGHLIGHTS

- Our revenue for the six months period ended June 30, 2025 was USD161.4 million, representing an increase of 33.1% from USD121.3 million for the six months period ended June 30, 2024.

  (i) Our revenue generated from the mainland China market was USD89.7 million in the six months period ended June 30, 2025, as compared with USD89.1 million in the six months period ended June 30, 2024.

  (ii) Our revenue generated from the global markets outside of mainland China was USD71.7 million in the six months period ended June 30, 2025, as compared with USD32.1 million in the six months period ended June 30, 2024.

- Our total clear aligner case shipments were approximately 225,800 in the six months period ended June 30, 2025, representing an increase of 47.7% from approximately 152,900 in the six months period ended June 30, 2024.

  (i) In the mainland China market, our clear aligner case shipments were approximately 108,600 in the six months period ended June 30, 2025, representing an increase of 14.0% from approximately 95,300 in the six months period ended June 30, 2024, driven by strategic pricing adjustments in response to intense competition.

(ii) In the global markets outside of mainland China, our clear aligner case shipments, including AngelAligner-branded aligners, Aditek-branded aligners and made-to-order aligners for simple cases for key strategic accounts, were approximately 117,200 in the six months period ended June 30, 2025, representing an increase of 103.5% from approximately 57,600 in the six months period ended June 30, 2024.

- Our gross profit for the six months period ended June 30, 2025 was USD100.6 million, representing an increase of 32.9% from USD75.7 million for the six months period ended June 30, 2024. Our gross profit margin for the six months period ended June 30, 2025 remained relatively stable at 62.4% as compared with the gross profit margin for the six months period ended June 30, 2024, primarily because we are still using treatment planning center and manufacturing sites based in mainland China, and we are in the process of expanding such centers and sites to outside of mainland China.

- Our net profit for the six months period ended June 30, 2025, including interest income on deposits and gains on wealth management products totalled USD8.8 million, was USD14.2 million, representing an increase of 583.6% from USD2.1 million for the six months period ended June 30, 2024. Our net profit margin for the six months period ended June 30, 2025 was 8.8%, recovering from 1.7% for the six months period ended June 30, 2024.

- Our adjusted net profit for the six months period ended June 30, 2025, including interest income on deposits and gains on wealth management products totalled USD8.8 million, was USD19.5 million, representing an increase of 84.8% from USD10.5 million for the six months period ended June 30, 2024.[1] Our adjusted net profit margin for the six months period ended June 30, 2025 was 12.1%, recovering from 8.3% for the six months period ended June 30, 2024.

- Our segment operating results for the six months period ended June 30, 2025 were as follows:

  (i) Our segment operating profit in the mainland China market for the six months period ended June 30, 2025 was USD17.2 million, representing an increase of 52.1% from USD11.3 million for the six months period ended June 30, 2024. Our segment operating profit margin in the mainland China market for the six months period ended June 30, 2025 was 19.2%, representing an increase of 6.5 percentage points from 12.7% for the six months period ended June 30, 2024. The increase was primarily driven by the reduction in allocation of shared operating expenses as a result of increased Group revenue and the implementation of expense reduction initiatives.

  (ii) Our segment operating loss in the global markets outside of mainland China was USD5.4 million in the six months period ended June 30, 2025, as compared with a loss of USD16.7 million in the six months period ended June 30, 2024. The narrowed loss was primarily attributable to the delayed operation of our treatment planning centers and manufacturing sites outside of mainland China, the delay in recruitment of certain sales and marketing, clinical support and customer service personnel, as well as the benefits of increased business scale.

- The Board has resolved to declare the payment of a special interim dividend of HKD0.46 per share for the six months period ended June 30, 2025.

Notes

(1) Adjusted net profit is defined as net profit with adjustments of share-based payments, unrealized fair value (losses)/gains recognized in profit or loss in relation to unlisted equity investment, amortization in relation to acquisition and net foreign exchange gains/(losses). Please refer to pages 15 to 16 of this announcement for more details.

(2) To align with the Group's globalization strategy and enable the shareholders and potential investors of the Company to have a clearer and more direct understanding of our financial performance, on February 19, 2025, the Company decided to adopt USD as the presentation currency for its consolidated financial statements, effective from the consolidated financial statements of the Group for the year ended December 31, 2024, which will be applied retrospectively. As such, the comparative figures for the six months period ended June 30, 2024 were restated in USD within this announcement.

MANAGEMENT DISCUSSION AND ANALYSIS[1]

Business Review

The Company delivered solid performance for the first half of 2025. The growth in case shipments, along with efficient operations at treatment planning centers and clear aligner manufacturing sites, drove year-over-year improvements in revenue, gross profit, and operating profit. The Company's profitability for the Reporting Period also benefited from stringent expense management in anticipation of a more challenging tariff environment, including the delay in recruitment of certain sales and marketing, clinical support and customer service personnel, as well as delay in operating our treatment planning centers and manufacturing sites outside of mainland China. Case shipments in the global markets outside of Mainland China, including AngelAligner-branded aligners, Aditek-branded aligners and made-to-order aligners for simple cases for key strategic accounts, increased rapidly during the Reporting Period, which marks the initial success from entering new markets and benefiting from the low hanging fruits. Looking ahead, we expect to increase investments in sales and marketing, clinical support and customer services, setting up and operating ex-China treatment planning centers and manufacturing sites, continuously strengthening legal capabilities to advance IP strategy and compliance, and further upgrading our data security infrastructure, to build a more sustainable international presence. Notwithstanding these planned investments, we remain confident in the Group's long-term prospects.

1. Go Global, Stay Local

In mainland China, we have implemented a forward-looking growth strategy, prioritizing early orthodontic treatment and lower-tier markets as drivers of sustainable growth. During the Reporting Period, we achieved approximately 108,600 clear aligner case shipments, representing a 14.0% year-over-year increase.

- In the field of early orthodontic treatment, we worked to enhance public awareness of the benefits of early intervention in children's oral health and bolstered Angel's brand influence. During the Reporting Period, the proportion of case shipments of Angel KiD products continued to grow, demonstrating strong market recognition of early orthodontic treatment.

- In lower-tier markets, we continue to enhance the professional capabilities of our sales and clinical teams. In July, we also completed a strategic investment in Shuyaqi, a clear aligner brand known for its cost-effective products and extensive clinic network to accelerate market penetration. During the Reporting Period, the proportion of case shipments to lower-tier markets steadily increased.

We have broadened our market reach outside of mainland China by offering high-quality treatment planning support, reliable deliveries, and continuous educational training programs by key opinion leaders (KOLs), as well as made-to-order aligners for simple cases for key strategic accounts. During the Reporting Period, our global markets, excluding mainland China, achieved approximately 117,200 clear aligner case shipments, which include AngelAligner-branded aligners, Aditek-branded aligners and made-to-order aligners for simple cases for key strategic accounts, representing a 103.5% year-over-year increase. This reflects both the low base of our business in the previous year and the initial success from entering new markets where we previously had no presence and benefiting from low hanging fruits. Looking ahead, we expect to increase investments in sales and marketing, clinical support and customer services to build a more material and sustainable presence.

[1] The products and technologies described in this section are available for use in specific countries and regions.

2. Product Innovation

In select markets, we have introduced two innovative solutions and products:

- **A10 Arch Expansion Solution:** We have developed a tiered treatment protocol for maxillary transverse deficiency and narrow dental arches in children. Our clear aligners dynamically guide arch development, enhancing both facial aesthetics and occlusal function. For moderate-to-severe cases, we have launched the innovative Angel Palatal Expander, which features high-stiffness materials and a novel palatal structural design. This advancement significantly increases expansion efficiency and improves clinical outcomes.

- **AngelActivator HG Functional Appliance:** This pioneering appliance, which was engineered for the treatment of complex Class II high-angle malocclusions, surpasses the limitations of traditional clear aligner approaches. Integrating the principles of a classic headgear activator with our clear aligner system enables a dual-treatment mode of daytime tooth alignment and nighttime mandibular advancement. This approach enhances treatment efficiency and patient compliance. The AngelActivator sets a new standard for the early orthodontic treatment of Class II high-angle cases.

For adults, we have focused on overcoming clinical challenges in complex cases, such as deep overbites and scissors bites. In select markets, we have introduced two innovative products:

- **Angel Scissors-bite Turbo:** To address the complexity and limited efficiency in treating scissors bite, we introduced the Angel Scissors-bite Turbo, which features an occlusal interactive ramp design that leverages the patient's bite force to achieve controlled intrusion and torque. This corrects the scissors bite, simplifies clinical procedures, and improves treatment outcomes.

- **Angel Enhanced Curve Turbo:** Designed to correct deep overbites, which are common yet complex malocclusions, the Angel Enhanced Curve Turbo incorporates a biomimetic curved surface that conforms to the motion of the lower incisors. It allows precise control of mandibular positioning and provides a more efficient clear aligner solution for these cases.

3. Digital Transformation, Redefining the Orthodontic Treatment Experience

Integration of computer technology is transforming the clear aligner industry. We are incorporating intelligent initial consultations, real-time treatment planning, and treatment monitoring tools into our clear aligner solutions. This drives improvements for clinicians, their staff, and their patients.

- The "Mooeli" intraoral monitoring device is being used in mainland China to monitor orthodontic progress. In markets outside of mainland China, the iOrtho™ platform of Angel has achieved software integration with a leading global provider of remote monitoring solutions. This collaboration allows dental professionals to order refinement aligners remotely and reduces the need for in-practice appointments.

We continue to apply cutting-edge computer technologies to make service more efficient. For example, in mainland China, we have introduced Angel Smart Assistant, an intelligent assistant that answers natural language queries by quickly retrieving treatment plans, significantly reducing information retrieval time.

4. Driven by Innovation, Advancing Clinical Value

Through R&D investment, we have fortified our technological offerings and broadened the scope of clear aligner indications.

In the first half of 2025, we expanded our efforts in technological innovation, particularly in early orthodontic treatment, complex cases, and digital dentistry. We launched a series of innovative products and solutions:

- In select markets, we introduced the industry's first anti-caries clear aligner, leveraging innovations in materials and structure to address oral health concerns during orthodontic treatment.

- In select markets, we unveiled several digital products, including iOrtho™ 2025 and the AngelScanner A8 intraoral scanner.

We have conducted research with several universities to produce clinical innovation, including:

- "Force Distributions Associated with Different Elastic Traction Methods for Maxillary Dentition Distalization by Clear Aligners: an In-Vitro Study" published in the SCI journal *BMC Oral Health* – which further validates the technical advantages of our angelButton™ over traditional traction methods.

- "Biomechanical Effects of Different Initial Posterior Inclinations During Extraction Space Closure with Clear Aligners: A Finite Element Analysis" – published in the top-tier orthodontic journal *AJO-DO*, which provides insight into the biomechanics of various anterior retraction strategies.

- "Cross-Center Model Adaptive Tooth Segmentation" – published in the leading medical imaging journal *Medical Image Analysis*, – which proposes a framework for Cross-center Model Adaptive Tooth segmentation (CMAT).

These research findings validate our commitment to evidence-based innovation in the clear aligner industry.

Intellectual property ("**IP**") strategy and compliance in connection with our R&D remain core priorities. As we have expanded our presence in the global markets, we have made considerable investments in strengthening our legal capabilities, and will increase our legal expenditure to further enhance IP compliance, drive IP innovation, and vigorously defend our IP rights.

5. Global Intelligent Manufacturing, Localized Services

We are committed to building a world-class, intelligent manufacturing system that prioritizes user-centricity, environmental sustainability, and scalability. In the first half of 2025, we strengthened our global supply chain to provide efficient and reliable support in all markets.

To support the rapid expansion of our global business, we have initiated the development of a more resilient and diversified global supply chain. As part of this initiative, we plan to establish or expand manufacturing and treatment planning facilities in key locations worldwide, as an example, our treatment planning centers in Brazil and Southeast Asia are currently providing treatment planning services for the United States. This evolving network will ensure a timely and stable supply of products and services for our global customers.

We have also devoted substantial resources to upgrading our data security infrastructure and our operational processes to ensure compliance with data security and privacy regulations in all major countries and regions we operate in. These efforts represent a significant investment so far and will remain a significant ongoing effort of the Group.

Outlook

We remain confident in the long-term growth prospects of the global clear aligner industry, despite recent macro-economic headwinds as well as industry volatilities. We will continue to leverage digital innovations to help dental professionals enhance their diagnosis precision and drive greater accessibility of clear aligner solutions. We plan to:

- Strengthen R&D capabilities to continue innovating clear aligner treatment solutions, expanding indications, and improving treatment outcomes;

- Increase investment in IT, legal and operational teams and infrastructure to ensure full compliance with the data security and privacy regulations in major jurisdictions;

- Enhance legal capabilities, increase legal expenditures to further enhance IP compliance, IP innovation, and to vigorously defend our IP rights;

- Optimize clinical capabilities to improve our users' experience and satisfaction, further building out our international sales, training and customer support teams and infrastructure;

- Expand production capacity and improve production efficiency to meet growing market demand, in particular, setting up and operating our treatment planning centers and manufacturing sites and teams outside of mainland China to ensure resilience and reliability of our supply chain;

- Expand our sales network, reinforce brand recognition, and increase market influence among KOLs and the academics; and

- Continue to expand in global markets to achieve balanced business development across multiple regions.

We will navigate the challenges posed by macro-economic and policy uncertainties, a slower-than-expected global economic recovery, geopolitical tensions, and adverse regulatory developments such as the Volume-based Procurement (VBP) program in mainland China, unfavorable trade tariffs and data privacy regulations. These factors could lead to a decline in orthodontic treatment volumes, which might adversely impact our performance. Therefore, we will monitor these global dynamics and assess their potential impact on our business. We will develop timely strategies to address these uncertainties and challenges to ensure sustainable growth of our business.

Financial Review

The following discussions are based on the financial information and notes set out in other sections of this announcement and should be read in conjunction with them.

Revenue

Our revenue increased by 33.1% from USD121.3 million for the six months period ended June 30, 2024 to USD161.4 million for the six months period ended June 30, 2025. The following table sets forth a breakdown of our revenue, both in absolute amounts and as a percentage of total revenue, by business line for the periods indicated.

	Six months ended June 30,			
	2025		2024	
	USD'000	*%*	*USD'000 (Restated)*	*%*
Clear aligner treatment solutions	**86,234**	**53.4**	84,470	69.7
Sales of clear aligners	**70,991**	**44.0**	31,938	26.3
Sales of other products	**3,107**	**1.9**	3,595	3.1
Other services	**1,022**	**0.7**	1,269	0.9
Total	**161,354**	**100.0**	121,272	100.0

- *Clear aligner treatment solutions.* Revenue generated from clear aligner treatment solutions mainly represents the revenue generated from provision of clear aligner treatment solutions to our clients in the mainland China market. Our revenue generated from the provision of clear aligner treatment solutions increased by 2.1% from USD84.5 million in the six months period ended June 30, 2024 to USD86.2 million in the six months period ended June 30, 2025, primarily due to the strategic pricing adjustments in response to intense competition in mainland China market, which contribute to the increase in case shipments, while the benefit was partially offset by the decrease in average sales price. Our revenue is also affected by the frequency of delivery of clear aligners and the number of sets contained in each delivered batch, which are typically dependent on the product line involved and the complexity of the relevant treatment plan, subject to a number of factors, such as specific demand of our dental professionals and our production capacity in the Reporting Period.

- *Sales of clear aligners.* Revenue generated from sales of clear aligners mainly represents the revenue generated from the sales of clear aligners to our clients in the global markets outside of mainland China, including AngelAligner-branded aligners, Aditek-branded aligners and made-to-order aligners for simple cases for key strategic accounts. Our revenue generated from sales of clear aligners substantially increased by 122.3% from USD31.9 million in the six months period ended June 30, 2024 to USD71.0 million in the six months period ended June 30, 2025.

- *Sales of other products.* Revenue generated from sales of other products mainly represents the revenue generated from the sales of Mooeli, oral consumer goods and other products. Our revenue generated from sales of other products decreased by 13.6% from approximately USD3.6 million in the six months period ended June 30, 2024 to USD3.1 million in the six months period ended June 30, 2025.

- *Other services.* Revenue generated from other services primarily represented service fees generated by our dental clinic for the provision of orthodontics and cosmetic dentistry services. Our revenue generated from other services decreased by 19.5% from USD1.3 million in the six months period ended June 30, 2024 to USD1.0 million in the six months period ended June 30, 2025.

Cost of revenue

Our cost of revenue increased by 33.3% from USD45.6 million in the six months period ended June 30, 2024 to USD60.7 million in the six months period ended June 30, 2025, primarily due to the cost increase incurred with the expansion of our business in the global markets outside of mainland China.

Gross profit and gross profit margin

Our gross profit increased by 32.9% from USD75.7 million in the six months period ended June 30, 2024 to USD100.6 million in the six months period ended June 30, 2025. The gross profit margin for the six months period ended June 30, 2025 was 62.4%, which remained relatively stable as compared with the gross profit margin for the six months period ended June 30, 2024, primarily because we are still using treatment planning center and manufacturing sites based in mainland China, and we are in the process of expanding such centers and sites to outside of mainland China.

Selling and marketing expenses

Our selling and marketing expenses increased by 11.3% from USD48.3 million in the six months period ended June 30, 2024 to USD53.8 million in the six months period ended June 30, 2025, primarily due to the increase in the global marketing personnel associated with the expansion of our business. The sales expense ratio, which represents the percentage of selling and marketing expenses to total revenue, has decreased from 39.8% in the six months period ended June 30, 2024 to 33.3% in the six months period ended June 30, 2025, primarily due to our stringent expense management, as well as an increase in the operation leverage as our business grow.

Administrative expenses

Our administrative expenses slightly increased by 0.3% from USD22.2 million in the six months period ended June 30, 2024 to USD22.3 million in the six months period ended June 30, 2025. The administrative expense ratio, which represents the percentage of administrative expenses to total revenue, has decreased from 18.3% in the six months period ended June 30, 2024 to 13.8% in the six months period ended June 30, 2025, reflecting an increased operating efficiency brought by our stringent expense management as well as the business scaling with the expansion and development of our business globally.

Research and development expenses

Our R&D expenses increased from USD10.5 million in the six months period ended June 30, 2024, to USD12.8 million in the six months period ended June 30, 2025, primarily because we expanded our R&D investment during the Reporting Period. We have a highly efficient and focused R&D program that significantly leverages clinicians' feedback for core clinical improvements to support clinicians.

Net impairment losses on financial assets

We recorded net impairment losses on financial assets of USD3.0 million in the six months period ended June 30, 2025, as compared with USD0.2 million in the six months period ended June 30, 2024, primarily due to the increase of trade and other receivables during the Reporting Period.

Other income

We recorded other income of USD6.2 million in the six months period ended June 30, 2025, as compared with USD7.2 million in the six months period ended June 30, 2024, primarily due to the decrease in interest rate which resulted in the decrease of interest on term deposits with initial terms over three months.

Other gains/(losses) – net

We recorded other gains – net of USD0.1 million in the six months period ended June 30, 2025, as compared with other losses – net of USD1.0 million in the six months period ended June 30, 2024, primarily due to the net foreign exchange gains collected during the Reporting Period.

We have purchased and disposed some wealth management products during the Reporting Period, the profits of which were also recorded in other gains/(losses) – net. None of the purchase or sale of wealth management products during the Reporting Period was large enough to constitute notifiable transactions as defined under Chapter 14 of the Rules Governing the Listing of Securities (the "**Listing Rules**") on The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**").

Finance income

We recorded finance income of USD2.0 million in the six months period ended June 30, 2025, as compared with USD2.9 million in the six months period ended June 30, 2024, primarily due to the decrease in interest rate which resulted in the decrease of interest income on bank deposits.

Finance costs

We recorded finance costs of USD1.4 million in the six months period ended June 30, 2025, as compared with USD0.9 million in the six months period ended June 30, 2024, primarily due to the increase in interest expenses on bank borrowings.

Share of results of investments accounted for using the equity method

We recorded a share of loss of investment accounted for using the equity method of USD0.4 million in the six months period ended June 30, 2025, as compared with a loss of USD0.1 million in the six months period ended June 30, 2024.

Profit before income tax

As a result of the foregoing, we recorded profit before income tax of USD15.1 million in the six months period ended June 30, 2025, as compared with USD2.5 million in the six months period ended June 30, 2024.

Income tax expenses

Our income tax expenses in the six months period ended June 30, 2025 was USD0.9 million, as compared with USD0.4 million in the six months period ended June 30, 2024, primarily due to the increase in the profit before income tax.

Profit for the period

As a result of the foregoing, our net profit in the six months period ended June 30, 2025 was USD14.2 million, representing an increase of 583.6% from USD2.1 million in the six months period ended June 30, 2024. The net profit margin for the six months period ended June 30, 2025 was 8.8%, as compared with 1.7% for the six months period ended June 30, 2024. The results were driven by the delay in operation of our treatment planning centers and manufacturing sites outside of mainland China, the delay in recruitment of certain sales and marketing, clinical support and customer service personnel, as well as the benefits of increased business scale.

Liquidity, capital resources and capital structure

In the six months period ended June 30, 2025, our primary use of cash was to fund our working capital requirements and other recurring expenses. We satisfied our capital expenditures and working capital requirements primarily using our own funds and the proceeds from the Global Offering.

We have continued to maintain a healthy and sound financial position and have followed a set of funding and treasury policies to manage our capital resources and mitigate potential risks involved. Our current assets increased from USD491.7 million as at December 31, 2024 to USD558.7 million as at June 30, 2025, primarily due to the increase in the outstanding balance of wealth management products with variable return.

Cash positions

Our cash positions primarily consisted of cash and cash equivalents and term deposits products recorded as current assets. Our cash positions increased from USD339.1 million as at December 31, 2024 to USD344.2 million as at June 30, 2025.

The following table sets forth our cash flows for the periods indicated.

	Six months ended June 30,	
	2025	2024
	USD'000	*USD'000* *(Restated)*
Net cash generated from/(used in) operating activities	**17,535**	(18,578)
Net cash used in investing activities	**(187,076)**	(267,615)
Net cash generated from financing activities	**63,439**	40,651
Net decrease in cash and cash equivalents	**(106,102)**	(245,542)
Cash and cash equivalents at beginning of the period	**227,103**	379,734
Exchange gains/(losses) on cash and cash equivalents	**2,468**	(1,003)
Cash and cash equivalents at the end of the period	**123,469**	133,189

Exposure to exchange rate fluctuation

Our business is principally conducted in RMB, USD, EUR and Brazilian Real ("**BRL**"). The majority of our assets are denominated in USD and RMB. Historically, consolidated financial statements of our Group were presented in RMB. We are mainly subject to foreign exchange risks arising from translation exposure and commercial transactions made under foreign currencies. We do not have other significant exposure to foreign exchange risks.

We recognized net foreign exchange gains of USD4.1 million in the six months period ended June 30, 2025, as compared to net foreign exchange losses of USD1.1 million in the six months period ended June 30, 2024. In addition, in the six months period ended June 30, 2025, we recorded exchange differences on translation of the Company of USD5.1 million as other comprehensive loss, as compared with USD3.3 million in the six months period ended June 30, 2024, primarily due to the exchange rate fluctuation.

We have not implemented any hedging arrangements. We are managing our foreign exchange risks by closely monitoring the movements of the foreign currency rates, and will make certain arrangements to hedge the risks when necessary according to our treasury management strategy. Cash repatriation from the People's Republic of China (the "**PRC**") is subject to the rules and regulations of foreign exchange control promulgated by the PRC government. We did not have other significant exposure to foreign exchange risk.

Capital expenditure

For the six months period ended June 30, 2025, our total capital expenditure amounted to USD17.3 million, which primarily consisted of the cash paid for the purchase of property, plant and equipment in connection with the construction of the Chuangmei Center.

Capital commitments

Our capital commitments primarily consisted of property, plant and equipment investment for the Chuangmei Center construction. The following table sets forth a summary of our capital commitments as at the dates indicated.

	As at June 30, 2025	As at December 31, 2024
	USD'000	*USD'000 (Restated)*
Property, plant and equipment	**2,095**	1,788
Intangible assets	**1,188**	521
Total	**3,283**	2,309

Contingent liabilities

As at June 30, 2025, we did not have any material contingent liability, guarantee or any litigation or claim of material importance, pending or threatened against any member of the Group.

Future plans for material investments and capital assets

Save as disclosed in this announcement, as at June 30, 2025, we did not have other substantial future plans for material investments and capital assets.

Material acquisitions and disposals of subsidiaries and affiliated companies

In the six months period ended June 30, 2025, we did not have any material acquisitions or disposals of subsidiaries and affiliated companies.

Significant investments and acquisition of capital assets

Save as disclosed in this announcement, in the six months period ended June 30, 2025, we did not hold any significant investments nor made any significant acquisition of capital assets.

Charge on the Group's assets

As at June 30, 2025, we had pledged certain property, plant and equipment in Brazil with a net carrying value of BRL29.1 million, equivalent to USD5.3 million for the banking facilities granted to Aditek to finance its daily working capital and capital expenditure plans.

Save as disclosed above, as at June 30, 2025, we had no other charges on our assets.

Bank borrowings and gearing ratio

As at June 30, 2025, our bank borrowings amounted to USD79.2 million, which consisted of bank borrowings made by Aditek (denominated in BRL) and credit loans (denominated in RMB). The gearing ratio as at June 30, 2025 is approximately 16.4%, which represents the percentage of bank borrowings to total equity.

Key financial indicators

The following table sets forth certain of our key financial ratios as at the dates and for the periods indicated.

	Six months ended June 30,	
	2025	2024
Profitability ratios		
Gross profit margin[1]	**62.4%**	62.4%
Net profit margin[2]	**8.8%**	1.7%
Adjusted net profit margin[3]	**12.1%**	8.3%
	As at June 30, 2025	As at December 31, 2024
Liquidity ratio		
Current ratio[4]	**2.8**	3.8

Notes

(1) The calculation of gross profit margin is based on gross profit divided by revenue for the period indicated and multiplied by 100.0%.

(2) The calculation of net profit margin is based on net profit divided by revenue for the period indicated and multiplied by 100.0%.

(3) The calculation of adjusted net profit margin, a non-IFRS measure, is based on adjusted net profit divided by revenue for the period indicated and multiplied by 100.0%.

(4) The calculation of current ratio is based on current assets divided by current liabilities as at the dates indicated.

NON-IFRS MEASURES

To supplement our condensed consolidated financial statements which are presented in accordance with the IFRS, we use adjusted EBITDA and adjusted net profit as additional financial measures, which are not required by or presented in accordance with the IFRS. To help the users of the financial statements to have a better understanding on the operating results of the Company, we define: (1) adjusted EBITDA as EBITDA (which is profit before income tax plus depreciation of property, plant and equipment, depreciation of right-of-use assets, and amortization of intangible assets, less interest income recorded as finance income) for the period with adjustments of certain items which are not closely related to major operations including share-based payments, unrealized fair value (losses)/gains of investment in relation to unlisted equity investments and net foreign exchange gains/(losses), and (2) adjusted net profit as profit for the period adjusted by certain items, including share-based payments, amortization of intangible assets related to certain acquisitions, unrealized fair value (losses)/gains of investment in relation to unlisted equity investments and net foreign exchange gain.

We believe that these non-IFRS measures facilitate comparisons of operating performance from period to period by eliminating potential impacts of items that our management does not consider indicative of our operating performance.

The following table reconciles our adjusted segment operating profits/(losses) for the periods indicated.

	Six months ended June 30,			
	2025		2024	
	Mainland China business	**Global business**	Mainland China business	Global business
	USD'000		*USD'000 (Restated)*	
Segment operating profits/(losses)	**17,185**	**(5,433)**	11,299	(16,656)
Add:				
Share-based payments	**2,496**	**1,865**	4,604	579
Adjusted segment operating profits/(losses)	**19,681**	**(3,568)**	15,903	(16,077)

The following table reconciles our adjusted EBITDA and adjusted net profit for the periods indicated.

	Six months ended June 30,	
	2025	2024
	USD'000	*USD'000* *(Restated)*
Profit for the period	**14,172**	2,073
Add:		
Income tax expenses	**909**	394
Profit before income tax	**15,081**	2,467
Add:		
Depreciation of property, plant and equipment	**5,145**	4,015
Depreciation of right-of-use assets	**2,490**	2,230
Amortization of intangible assets	**1,169**	1,175
(Finance income – net)	**(528)**	(2,016)
EBITDA	**23,357**	7,871
Add:		
Share-based payments	**4,361**	5,183
Unrealized fair value losses recognized in profit or loss in relation to unlisted equity investment	**4,554**	1,663
Net foreign exchange (gains)/losses	**(4,094)**	1,104
Adjusted EBITDA	**28,178**	15,821
Profit for the period	**14,172**	2,073
Add:		
Share-based payments	**4,361**	5,183
Amortization in relation to acquisition	**476**	511
Unrealized fair value losses recognized in profit or loss in relation to unlisted equity investment	**4,554**	1,663
Net foreign exchange (gains)/losses	**(4,094)**	1,104
Adjusted net profit	**19,469**	10,534

INTERIM CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

	Note	Six months ended June 30, 2025 USD'000 (Unaudited)	2024 USD'000 (Unaudited) (Restated)
Revenue	*6*	**161,354**	121,272
Cost of revenue	*7*	**(60,746)**	(45,558)
Gross profit		**100,608**	75,714
Selling and marketing expenses	*7*	**(53,757)**	(48,301)
Administrative expenses	*7*	**(22,288)**	(22,231)
Research and development expenses	*7*	**(12,811)**	(10,539)
Net impairment losses on financial assets		**(2,964)**	(188)
Other income	*8*	**6,226**	7,234
Other expenses	*8*	**(163)**	(141)
Other gains/(losses) – net	*8*	**88**	(1,026)
Operating profit		**14,939**	522
Finance income	*9*	**1,951**	2,937
Finance costs	*9*	**(1,423)**	(921)
Finance income – net	*9*	**528**	2,016
Share of results of investments accounted for using the equity method		**(386)**	(71)
Profit before income tax		**15,081**	2,467
Income tax expense	*10*	**(909)**	(394)
Profit for the period		**14,172**	2,073
Profit attributable to			
– Owners of the Company		**14,643**	3,165
– Non-controlling interests		**(471)**	(1,092)
Other comprehensive income/(loss)			
Items that will not be reclassified to profit or loss			
Exchange differences on translation of the Company and attributed non-controlling interests		**(3,889)**	(707)
Items that may be subsequently reclassified to profit or loss			
Exchange differences on translation of subsidiaries		**2,866**	(3,019)
		(1,023)	(3,726)
Total comprehensive income/(loss) for the period		**13,149**	(1,653)

	Note	Six months ended June 30, 2025 USD'000 (Unaudited)	2024 USD'000 (Unaudited) (Restated)
Total comprehensive income/(loss) for the period attributable to:			
– Owners of the Company		**12,414**	479
– Non-controlling interests		**735**	(2,132)
		13,149	(1,653)
Earnings per share for profit attributable to owners of the Company (expressed in USD per share)			
– Basic	*11*	**0.09**	0.02
– Diluted	*11*	**0.09**	0.02

The above condensed consolidated statement of comprehensive income should be read in conjunction with the accompanying notes.

INTERIM CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION

	Note	**As at June 30, 2025** ***USD'000*** ***(Unaudited)***	As at December 31, 2024 *USD'000* *(Audited)*
ASSETS			
Non-current assets			
Property, plant and equipment	*12*	**81,305**	75,295
Intangible assets	*13*	**19,264**	18,365
Right-of-use assets	*14*	**18,348**	17,924
Investments accounted for using the equity method		**13,300**	5,237
Deferred tax assets		**9,359**	7,491
Financial assets at fair value through profit or loss	*18*	**37,424**	38,615
Term deposits with initial terms over three months		**26,914**	14,345
Trade and other receivables and prepayments	*16*	**15,849**	9,167
		221,763	186,439
Current assets			
Inventories		**17,234**	18,360
Trade and other receivables and prepayments	*16*	**53,814**	36,384
Financial assets at fair value through profit or loss	*18*	**143,339**	97,778
Restricted cash		**109**	99
Term deposits with initial terms over three months	*17*	**220,736**	111,948
Cash and cash equivalents	*17*	**123,469**	227,103
		558,701	491,672
Total assets		**780,464**	678,111
EQUITY AND LIABILITIES			
Equity attributable to owners of the Company			
Share capital	*19*	**17**	17
Share premium	*19*	**407,111**	415,426
Shares held for employee share scheme	*19*	*****	*
Other reserves		**(22,836)**	(17,835)
Retained earnings		**91,138**	76,495
		475,430	474,103
Non-controlling interests		**6,874**	6,139
Total equity		**482,304**	480,242

* The balance represents an amount less than USD1,000.

	Note	As at June 30, 2025 USD'000 (Unaudited)	As at December 31, 2024 USD'000 (Audited)
LIABILITIES			
Non-current liabilities			
Bank borrowings	*22*	**792**	488
Contract liabilities		**41,784**	21,168
Lease liabilities		**6,455**	6,959
Deferred income		**4,050**	4,240
Deferred tax liabilities		**2,596**	2,553
Other non-current liabilities	*23*	**41,419**	34,368
		97,096	69,776
Current liabilities			
Bank borrowings	*22*	**78,382**	2,860
Trade and other payables	*21*	**58,360**	63,432
Contract liabilities		**56,844**	56,672
Current income tax liabilities		**2,143**	953
Lease liabilities		**5,335**	4,176
		201,064	128,093
Total liabilities		**298,160**	197,869
Total equity and liabilities		**780,464**	678,111

The above condensed consolidated statement of financial position should be read in conjunction with the accompanying notes.

Approved by the Board of Directors on August 25, 2025 and were signed on its behalf.

Mr. Hu Jiezhang	**Ms. Dong Li**
Director	*Director*

INTERIM CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

	Note	Attributable to owners of the Company							
		Share capital USD'000	Share premium USD'000	Shares held for employee share scheme USD'000	Other reserves USD'000	Retained earnings USD'000	Total USD'000	Non-controlling interests USD'000	Total equity USD'000
(Unaudited)									
Balance at January 1, 2025		17	415,426	*	(17,835)	76,495	474,103	6,139	480,242
Comprehensive income									
Profit for the period		–	–	–	–	14,643	14,643	(471)	14,172
Other comprehensive income									
– Currency translation differences		–	–	–	(2,229)	–	(2,229)	1,206	(1,023)
Total comprehensive income for the period		–	–	–	(2,229)	14,643	12,414	735	13,149
Transactions with owners in their capacity as owners									
Equity-settled share-based payment transactions	*20*	–	–	–	4,361	–	4,361	–	4,361
Shares issued for restricted share award scheme	*19*	*	–	*	–	–	–	–	–
Transfer of shares held for employee share scheme upon vesting		*	–	*	–	–	–	–	–
Dividends declared	*19*	–	(8,315)	–	–	–	(8,315)	–	(8,315)
Changes in put option liabilities in respect of non-controlling interests	*23*	–	–	–	(7,133)	–	(7,133)	–	(7,133)
Total transactions with owners in their capacity as owners		*	(8,315)	*	(2,772)	–	(11,087)	–	(11,087)
Balance at June 30, 2025		17	407,111	*	(22,836)	91,138	475,430	6,874	482,304

* The balance represents an amount less than USD1,000.

	Note	Attributable to owners of the Company							
		Share capital	Share premium	Shares held for employee share scheme	Other reserves	Retained earnings	Total	Non-controlling interests	Total equity
		USD'000	*USD'000*	*USD'000*	*USD'000*	*USD'000*	*USD'000*	*USD'000*	*USD'000*
(Unaudited)									
Balance at January 1, 2024		17	439,086	*	(35,577)	67,546	471,072	10,058	481,130
Comprehensive income									
Profit for the period		–	–	–	–	3,165	3,165	(1,092)	2,073
Other comprehensive income									
– Currency translation differences		–	–	–	(2,686)	–	(2,686)	(1,040)	(3,726)
Total comprehensive income for the period		–	–	–	(2,686)	3,165	479	(2,132)	(1,653)
Transactions with owners in their capacity as owners									
Equity-settled share-based payment transactions	*20*	–	–	–	5,183	–	5,183	–	5,183
Shares issued for restricted share award scheme	*19*	*	–	*	–	–	–	–	–
Transfer of shares held for employee share scheme upon vesting		*	–	*	–	–	–	–	–
Dividends declared	*19*	–	(23,837)	–	–	–	(23,837)	–	(23,837)
Repurchase and cancellation of shares	*19*	*	(130)	–	–	–	(130)	–	(130)
Changes in put option liabilities in respect of non-controlling interests	*23*	–	–	–	748	–	748	–	748
Total transactions with owners in their capacity as owners		*	(23,967)	*	5,931	–	(18,036)	–	(18,036)
Balance at June 30, 2024 (Restated)		17	415,119	*	(32,332)	70,711	453,515	7,926	461,441

* The balance represents an amount less than USD1,000.

The above condensed consolidated statement of changes in equity should be read in conjunction with the accompanying notes.

INTERIM CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

	Note	Six months ended June 30, 2025 USD'000 (Unaudited)	2024 USD'000 (Unaudited) (Restated)
Cash flows from operating activities			
Cash used in operations		**19,219**	(14,671)
Income tax paid		**(1,684)**	(3,907)
Net cash generated from/(used in) operating activities		**17,535**	(18,578)
Cash flows from investing activities			
Purchases of property, plant and equipment and other non-current assets		**(16,755)**	(14,604)
Purchases of intangible assets		**(531)**	(257)
Proceeds from disposal of property, plant and equipment		**454**	157
Investment in associate and joint venture		**(8,364)**	(4,223)
Purchase of term deposit with initial terms over three months		**(347,793)**	(261,977)
Proceeds from term deposit with initial terms over three months		**226,930**	–
Purchases of financial assets at fair value through profit or loss		**(367,575)**	(204,890)
Proceeds from disposals of financial assets at fair value through profit or loss		**320,565**	216,806
Proceeds of loans repaid by employees		**77**	233
Loans provided to third parties		**–**	(3,173)
Interest received		**5,916**	4,313
Net cash used in investing activities		**(187,076)**	(267,615)
Cash flows from financing activities			
Dividend paid		**(8,315)**	–
Proceeds from bank borrowings		**76,609**	44,319
Borrowing interest paid		**(1,131)**	(543)
Repayments of bank borrowings		**(1,348)**	(869)
Principal elements of lease payments		**(2,084)**	(1,783)
Interest paid of lease liabilities		**(292)**	(343)
Payments for shares bought back		**–**	(130)
Net cash generated from financing activities		**63,439**	40,651
Net decrease in cash and cash equivalents		**(106,102)**	(245,542)
Cash and cash equivalents at beginning of the period		**227,103**	379,734
Exchange gains/(losses) on cash and cash equivalents		**2,468**	(1,003)
Cash and cash equivalents at the end of the period		**123,469**	133,189

The above condensed consolidated statement of cash flows should be read in conjunction with the accompanying notes.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL INFORMATION

1 GENERAL INFORMATION

Angelalign Technology Inc. (the "**Company**") was incorporated in the Cayman Islands on November 29, 2018 as an exempted company with limited liability under the Companies Law, Cap.22 (Law 3 of 1961, as consolidated and revised) of the Cayman Islands. The address of its registered office is Maples Corporate Services Limited, PO Box 309, Ugland House, Grand Cayman, KY1-1104, Cayman Islands.

The Company is an investment holding company. The Company and its subsidiaries (together, the "**Group**") are principally engaged in the clear aligner treatment solutions and sales of aligners. CareCapital Group is the ultimate holder of the Company which controlled the business of the Group through CareCapital Orthotech Limited ("**CareCapital Orthotech**"), a company incorporated in Hong Kong.

The Company completed its initial public offering ("**IPO**") and listed its shares on the Main Board of The Stock Exchange of Hong Kong Limited ("**HKSE**") on June 16, 2021.

The Interim Financial Information for the six months ended June 30, 2025 (the "**Interim Financial Information**") is presented in United States Dollar ("**USD**"), unless otherwise stated, and was approved for issue by the Board of Directors of the Company on August 25, 2025.

2 BASIS OF PREPARATION

The Interim Financial Information has been prepared in accordance with International Accounting Standard ("**IAS**") 34 "Interim Financial Reporting". The Interim Financial Information does not include all of the notes normally included in an annual financial report. Accordingly, this report should be read in conjunction with the annual financial statements of the Group for the year ended December 31, 2024 (the "**2024 Financial Statements**"), which have been prepared in accordance with IFRS Accounting Standards issued by the International Accounting Standards Board ("**IASB**").

3 MATERIAL ACCOUNTING POLICIES

The accounting policies adopted are consistent with those of the 2024 Financial Statements, except for the adoption of new and amended IFRS Accounting Standards effective for the financial year beginning January 1, 2025.

(a) New standards and amendments adopted by the Group

The following standards and amendments apply for the first time to financial reporting periods commencing January 1, 2025:

		Effective for accounting periods beginning on or after
Amendments to IAS 21	Lack of Exchangeability	January 1, 2025

(b) New amendments not yet been adopted

		Effective for accounting periods beginning on or after
Annual Improvements to IFRS Accounting Standards – Volume 11	Clarifications, simplifications, corrections, and changes intended to improve consistency	January 1, 2026
Amendments to IFRS 9 and IFRS 7	Financial Instruments Standards	January 1, 2026
IFRS 18	Presentation and Disclosure in Financial Statements	January 1, 2027
IFRS 19	Subsidiaries without Public Accountability: Disclosures	January 1, 2027
Amendments to IFRS 10 and IAS 28	Sale or Contribution of Assets between an Investor and its Associate or Joint Venture	To be determined

Based on management's preliminary assessment, none of the above amendments is expected to have a significant impact on the Group's consolidated financial statements.

4 CRITICAL ACCOUNTING ESTIMATES AND JUDGEMENTS

The preparation of Interim Financial Information requires management to make judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets and liabilities, income and expenses. Actual results may differ from these estimates.

In preparing this Interim Financial Information, the significant judgements made by management in applying the Group's accounting policies and the key sources of estimation uncertainty were the same as those that applied to the 2024 Financial Statements.

5 FINANCIAL RISK MANAGEMENT

5.1 Financial risk factors

The Group's activities expose it to a variety of financial risks: market risk (including foreign exchange risk, cash flow and fair value interest rate risk), credit risk and liquidity risk.

The Interim Financial Information does not include all financial risk management information and disclosures required in the 2024 Financial Statements, and should be read in conjunction with the 2024 Financial Statements.

There have been no significant changes in the risk factors and management policies since the year ended December 31, 2024.

(a) Liquidity risk

To manage the liquidity risk, management monitors rolling forecasts of the Group's liquidity reserve (comprising undrawn banking facilities) and cash and cash equivalents on the basis of expected cash flow. The Group expects to fund the future cash flow needs mainly through internally generated cash flows from operations.

The table below analyses the Group's financial liabilities into relevant maturity groupings based on the remaining period at the statement of financial position dates to the contractual maturity date. The amounts disclosed in the table are the contractual undiscounted cash flows.

	Less than 1 year *USD'000*	Between 1 and 2 years *USD'000*	Between 2 and 5 years *USD'000*	Over 5 years *USD'000*	Total *USD'000*
As at June 30, 2025 (Unaudited)					
Lease liabilities	**5,443**	**3,749**	**4,552**	**424**	**14,168**
Trade and other payables excluding non-financial liabilities	**25,931**	**–**	**–**	**–**	**25,931**
Bank borrowings	**78,585**	**532**	**410**	**3**	**79,530**
Other non-current financial liabilities	**–**	**–**	**67,618**	**–**	**67,618**
Total	**109,959**	**4,281**	**72,580**	**427**	**187,247**
As at December 31, 2024 (Audited)					
Lease liabilities	4,632	3,647	3,205	621	12,105
Trade and other payables excluding non-financial liabilities	25,809	–	–	–	25,809
Bank borrowings	3,015	563	–	–	3,578
Other non-current financial liabilities	–	–	63,540	–	63,540
Total	33,456	4,210	66,745	621	105,032

5.2 Capital management

The Group's objectives when managing capital are to safeguard the Group's ability to continue as a going concern in order to provide returns for shareholders and benefits for other stakeholders and to maintain an optimal capital structure to reduce the cost of capital.

In order to maintain or adjust the capital structure, the Group may adjust the amount of dividends paid to shareholders, issue new shares or sell assets to reduce debt.

Consistent with others in the industry, the Group monitors capital on the basis of the gearing ratio. This ratio is calculated as net debt divided by total capital. Net debt is calculated as total debt less cash and cash equivalents. Total capital is calculated as "equity" as shown in the interim condensed consolidated statement of financial position.

As at June 30, 2025 and December 31, 2024, the Group maintained at net cash position.

5.3 Fair value estimation

The table below analyses the Group's financial instruments carried at fair value as at June 30, 2025 by level of the inputs to valuation techniques used to measure fair value. Such inputs are categorised into three levels within a fair value hierarchy as follows:

- Quoted prices (unadjusted) in active markets for identical assets or liabilities (level 1);
- Inputs other than quoted prices included within level 1 that are observable for the asset or liability, either directly (that is, as prices) or indirectly (that is, derived from prices) (level 2); and
- Inputs for the asset or liability that are not based on observable market data (that is, unobservable inputs) (level 3).

(a) Fair value hierarchy

As at June 30, 2025, the financial assets measured at fair value on a recurring basis by the above three levels were analysed below:

	Level 1 *USD'000*	**Level 2** *USD'000*	**Level 3** *USD'000*	**Total** *USD'000*
As at June 30, 2025 (Unaudited)				
Assets:				
Financial assets at fair value through profit or loss				
– Wealth management products with variable return	**–**	**143,339**	**–**	**143,339**
– Associate	**–**	**–**	**2,281**	**2,281**
– Other investees	**–**	**–**	**35,143**	**35,143**
	–	**143,339**	**37,424**	**180,763**

As at December 31, 2024, the financial assets measured at fair value on a recurring basis by the above three levels were analysed below:

	Level 1 *USD'000*	Level 2 *USD'000*	Level 3 *USD'000*	Total *USD'000*
As at December 31, 2024 (Audited)				
Assets:				
Financial assets at fair value through profit or loss				
– Wealth management products with variable return	–	97,778	–	97,778
– Associate	–	–	2,287	2,287
– Other investees	–	–	35,645	35,645
– Derivative financial asset	–	–	683	683
	–	97,778	38,615	136,393

During the six months ended June 30, 2025, there were no transfers between levels 1, 2 and 3.

The fair value of financial instruments traded in active markets is determined with reference to quoted market prices at the end of the reporting period. These instruments are included in level 1.

The fair value of financial instruments that are not traded in an active market is determined using valuation techniques that maximise the use of observable market data and rely as little as possible on entity-specific estimates. If all significant inputs required to fair value an instrument are observable, the instrument is included in level 2.

If one or more of the significant inputs are not based on observable market data, the instrument is included in level 3.

Specific valuation techniques used to value financial instruments include:

- Quoted market prices or dealer quotes for similar instruments;
- Black-Scholes Model and unobservable inputs, mainly including assumptions of expected volatility;
- The latest round financing, i.e. the prior transaction price or the third-party pricing information; and
- A combination of observable and unobservable inputs, mainly including expected volatility, risk-free interest rate, market multiples, etc.

The following table presents the changes in level 3 instruments during the period/year:

	As at June 30, 2025 ***USD'000*** **(Unaudited)**	As at December 31, 2024 *USD'000* (Audited)
Derivative financial asset		
Balance at the beginning of the year	**683**	1,214
Unrealized fair value losses recognized in profit or loss	**(727)**	(322)
Currency translation differences	**44**	(209)
Balance at the end of the period/year	**–**	683
Other investees		
Balance at the beginning of the year	**35,645**	34,206
Additions	**4,000**	3,408
Unrealized fair value losses recognized in profit or loss	**(4,538)**	(1,865)
Currency translation differences	**36**	(104)
Balance at the end of the period/year	**35,143**	35,645
Associate		
Balance at the beginning of the year	**2,287**	–
Additions	**–**	2,112
Unrealized fair value (losses)/gains recognized in profit or loss	**(16)**	202
Currency translation differences	**10**	(27)
Balance at the end of the period/year	**2,281**	2,287

(b) Valuation processes inputs and relationships to fair value

The Group has a team that manages the valuation of level 2 and level 3 instruments for financial reporting purposes. The team manages the valuation exercise of the investments on a case-by-case basis. Every half year, the team would use valuation techniques to determine the fair value of the Group's level 2 and level 3 instruments. External valuation experts will be involved when necessary.

During the six months ended June 30, 2025, the Group purchased wealth management products with variable return based on forward exchange rates or gold prices at certain dates. The Group classified these wealth management products into level 2 financial instruments as the inputs included were observable. The fair value of financial instruments in level 2 is determined using valuation techniques with the use of observable market data such as the future cash flows based on foreign exchange rates or gold price and observable yield curve.

The components of the level 3 instruments include investments in unlisted companies classified as FVPL and derivative financial asset. As these investments and instruments are not traded in an active market, the majority of their fair values have been determined using applicable valuation techniques including comparable companies approach, comparable transactions approach and other option pricing approach. These valuation approaches require significant judgments, assumptions and inputs, including risk-free rates, expected volatility, relevant underlying financial projections, and market information of recent transactions (such as recent fund-raising transactions undertaken by the investees) and other exposures, etc.

The main level 3 inputs used by the Group are derived and evaluated as follows:

- Expected volatility for investment in unlisted equity investments and derivative financial asset are estimated based on average volatility for similar types of companies.

- Risk-free interest rate for investments in unlisted equity investments and derivative financial asset are derived from interest rates on treasury bonds over the same period.

The following table summarises the quantitative information about the significant unobservable inputs used in level 3 fair value measurements:

Description	Fair value at June 30, 2025 USD'000 (Unaudited)	Fair value at December 31, 2024 USD'000 (Audited)	Unobservable inputs	Range of inputs at June 30, 2025 USD'000 (Unaudited)	Range of inputs at December 31, 2024 USD'000 (Audited)	Relationship of unobservable inputs to fair value
Other investees	**35,143**	35,645	Expected volatility	**39.3%-65.2%**	41.1%-59.8%	Increased/decreased expected volatility by 100 basis points (bps), the fair value for investments in unlisted equity investments would have been approximately USD157,000 lower/USD160,000 higher (2024: USD153,000 lower/USD107,000 higher).
			Risk-free interest rate	**0.98%-4.79%**	1.08%-5.38%	Increased/decreased risk-free interest rate by 100 bps, the fair value for investments in unlisted equity investments would have been approximately USD344,000 lower/USD349,000 higher (2024: USD405,000 lower/USD414,000 higher).
Associate	**2,281**	2,287	Expected volatility	**53.2%-55.2%**	51.9%-53.9%	Increased/decreased expected volatility by 100 bps, the fair value would have been approximately USD4,000 lower/USD4,000 higher (2024: USD4,000 lower/USD182,000 higher).
Derivative financial asset	**–**	683	Expected volatility	**NA**	42.2%	Increased/decreased expected volatility by 100 bps, the fair value would have been approximately USD10,000 higher/lower in 2024.

The carrying amounts of the Group's financial assets and liabilities, including cash and cash equivalents, term deposits with initial terms over three months, restricted cash, trade and other receivables (excluding non-financial assets) less allowance for impairment, trade and other payables (excluding non-financial liabilities), lease liabilities, bank borrowings and other non-current financial liabilities approximated their fair values due to their short maturities.

6 REVENUE AND SEGMENT INFORMATION

	Six months ended June 30,	
	2025	2024
	USD'000	*USD'000*
	(Unaudited)	(Unaudited)
		(Restated)
Revenue from external customers is recognized over time and is derived from the rendering of:		
– Clear aligner treatment solutions	**86,234**	84,470
– Other services	**1,022**	1,269
Revenue from external customers is recognized at a point in time and is derived from:		
– Sales of clear aligners	**70,991**	31,938
– Sales of other products	**3,107**	3,595
Total revenue	**161,354**	121,272

The chief operating decision maker ("**CODM**") identifies operating segments based on the internal organization structure, management requirements and internal reporting system, and discloses segment information of reportable segments which is determined on the basis of operating segments. An operating segment is a component of the Group that satisfies all of the following conditions: (1) the component is able to earn revenues and incur expenses from its ordinary activities; (2) whose operating results are regularly reviewed by the Group's management to make decisions about resources to be allocated to the segment and to assess its performance; and (3) for which the information on financial position, operating results and cash flows is available to the Group.

Management monitors the results of the Group's operating segments separately for the purpose of making decisions about resource allocation and performance assessment. Segment performance is evaluated based on the reportable segment profit, which is measured consistently with the Group's profit before tax except that other unallocated income, gains and losses, net impairment losses on financial assets, finance income-net, and share of results of investments accounted for using the equity method are excluded from such measurement.

Segment revenue and results

As a result of this evaluation, the Group has the following reportable segments for six months ended June 30, 2025:

	Six months ended June 30, 2025		
	Mainland China business *USD'000* (Unaudited)	**Global business** *USD'000* (Unaudited)	**Consolidated** *USD'000* (Unaudited)
Revenue	**89,682**	**71,672**	**161,354**
Cost of sales	**(32,951)**	**(27,795)**	**(60,746)**
Gross profit	**56,731**	**43,877**	**100,608**
Segment operating profit/(loss)	**17,185**	**(5,433)**	**11,752**
Other unallocated income, gains and losses			**6,151**
Net impairment losses on financial assets			**(2,964)**
Finance income – net			**528**
Share of results of investments accounted for using the equity method			**(386)**
Profit before tax			**15,081**
Income tax expense			**(909)**
Profit for the Period			**14,172**
Other item			
Depreciation and amortization	**6,823**	**1,981**	**8,804**

As a result of this evaluation, the Group has the following reportable segments for six months ended June 30, 2024:

	Six months ended June 30, 2024		
	Mainland China business *USD'000* (Unaudited) (Restated)	Global business *USD'000* (Unaudited) (Restated)	Consolidated *USD'000* (Unaudited) (Restated)
Revenue	89,143	32,129	121,272
Cost of sales	(32,147)	(13,411)	(45,558)
Gross profit	56,996	18,718	75,714
Segment operating profit/(loss)	11,299	(16,656)	(5,357)
Other unallocated income, gains and losses			6,067
Net impairment losses on financial assets			(188)
Finance income – net			2,016
Share of results of investments accounted for using the equity method			(71)
Profit before tax			2,467
Income tax expense			(394)
Profit for the Period			2,073
Other item			
Depreciation and amortization	6,043	1,377	7,420

Geographical information

Information about the Group's non-current assets other than financial instruments and deferred tax assets is presented based on the geographical locations of the assets.

	As at June 30, 2025	As at December 31, 2024
	USD'000	*USD'000*
	(Unaudited)	(Audited)
Mainland China	**97,789**	87,280
Global regions	**34,428**	29,541
	132,217	116,821

Information about major customers

Since none of the Group's provision of services to a single customer amounting to 10% or more of the Group's total revenue for the periods ended June 30, 2025 and 2024, no major customer information is presented in accordance with IFRS 8 "Operating Segments".

7 EXPENSES BY NATURE

Expenses included in cost of revenue, selling and marketing expenses, administrative expenses and research and development expenses are analyzed below:

	Six months ended June 30,	
	2025	2024
	USD'000	*USD'000*
	(Unaudited)	(Unaudited) (Restated)
Changes in inventories of finished goods and work in progress	**(243)**	49
Raw materials and consumables used and other inventories	**19,243**	15,496
Employee benefit expenses	**76,913**	65,186
Delivery costs	**12,340**	6,109
Advertising and promotion expenses	**10,943**	11,977
Depreciation and amortization	**8,804**	7,420
Professional service and consulting fees	**6,646**	5,904
Travelling expenses	**4,231**	3,396
Outsourcing costs	**2,212**	3,562
Office expenses	**1,972**	1,359
Utility costs	**1,742**	1,257
Taxes and surcharges	**1,419**	1,008
Entertainment expenses	**1,018**	896
Auditor's remuneration		
– Interim review services	**195**	183
– Non-Audit services	**51**	250
Short-term lease and variable lease expenses	**66**	218
Others	**2,050**	2,359
	149,602	126,629

8 OTHER INCOME, OTHER EXPENSES AND OTHER GAINS/(LOSSES) – NET

	Six months ended June 30,	
	2025	2024
	USD'000	*USD'000*
	(Unaudited)	(Unaudited) (Restated)
Other income		
Interest on term deposits with initial terms over three months	**4,238**	5,253
Others	**1,988**	1,981
	6,226	7,234
Other expenses		
Donations	**(163)**	(141)
Other gains/(losses) – net		
Net foreign exchange gains/(losses)	**4,094**	(1,104)
Realized and unrealized (losses)/gains on financial assets at FVPL	**(2,680)**	4
Losses on disposals of property, plant and equipment	**(477)**	(15)
Others	**(849)**	89
	88	(1,026)

9 FINANCE INCOME – NET

	Six months ended June 30,	
	2025	2024
	USD'000	*USD'000*
	(Unaudited)	(Unaudited) (Restated)
Finance income:		
– Interest income on bank deposits	**1,951**	2,937
Finance costs:		
– Interest expense on lease liabilities	**(292)**	(343)
– Interest expense on bank borrowings	**(1,131)**	(578)
Finance income – net	**528**	2,016

10 INCOME TAX EXPENSE

	Six months ended June 30,	
	2025	2024
	USD'000	*USD'000*
	(Unaudited)	(Unaudited)
		(Restated)
Current income tax		
– Mainland China corporate income tax	**2,427**	3,035
– Other countries and regions taxes	**310**	48
	2,737	3,083
Deferred income tax		
– Mainland China corporate income tax	**(1,384)**	(1,755)
– Other countries and regions taxes	**(444)**	(934)
	(1,828)	(2,689)
	909	394

The tax on the Group's profit before income tax differs from the theoretical amount that would arise using the standard tax rate applicable to profit to the respective companies of the Group as follows:

	Six months ended June 30,	
	2025	2024
	USD'000	*USD'000*
	(Unaudited)	(Unaudited)
		(Restated)
Profit before income tax	**15,081**	2,467
Tax calculated at respective statutory tax rates	**3,802**	250
Tax effects of:		
– Effect of change in the tax rates for deferred tax of prior years	**–**	145
– Preferential income tax rates applicable to subsidiaries	**(1,019)**	(1,297)
– Expenses not deductible for taxation purposes	**706**	1,385
– Temporary differences and tax losses not recognized for deferred income tax in current year	**1,733**	2,117
– Super deduction for research and development expenditure	**(949)**	(938)
– Share of results of investments accounted for using the equity method	**57**	3
– Utilization of tax losses not recognized for deferred income tax in prior years	**(1,913)**	(166)
– Recognition of tax losses and temporary differences not recognized for deferred income tax in prior years	**(118)**	(143)
– Final settlement differences	**171**	36
– Income not subject to tax	**(1,561)**	(998)
	909	394

(a) Cayman Islands income tax

Under the prevailing laws of the Cayman Islands, the Company is not subject to tax on income or capital gains. In addition, no Cayman Islands withholding tax is payable on dividend payments by the Company to its shareholders.

(b) Mainland China corporate income tax ("CIT")

CIT provision was made on the estimated assessable profits of entities within the Group incorporated in Mainland China and was calculated in accordance with the relevant regulations of the PRC after considering the available tax benefits from refunds and allowance. The general Mainland China CIT rate is 25% during the six months ended June 30, 2025.

The Company's subsidiary, Wuxi EA Medical Instruments Technologies Limited (無錫時代天使醫療器械科技有限公司) ("**Wuxi EA**"), was approved as High and New Technology Enterprise ("**HNTE**") under the relevant tax rules and regulations of the PRC in 2014 and it has renewed the qualification of HNTE in 2017, 2020 and 2023, and accordingly, is subject to a reduced preferential CIT rate of 15% during the six months ended June 30, 2025.

The Company's subsidiary, Shanghai EA Medical Instruments Co., Ltd. (上海時代天使醫療器械有限公司, "**Shanghai EA**"), was approved as HNTE under the relevant tax rules and regulations of the PRC in 2019 and it has renewed the qualification of HNTE in 2022, and accordingly, is subject to a reduced preferential CIT rate of 15% during the six months ended June 30, 2025.

The Company's subsidiary, Wuxi EA Bio-Tech Co., Ltd. (無錫時代天使生物科技有限公司), was approved as HNTE under the relevant tax rules and regulations of the PRC in 2023 and accordingly, is subject to a reduced preferential CIT rate of 15% for the six months ended June 30, 2025.

According to the CIT laws and Detailed Implementation Rules, an enterprise is allowed to claim research and development expenses incurred for the development of new technologies, new products and new craftsmanship from 2008 onwards. From 2022, according to Cai Shui [2022] No.16 (財稅[2022]16號), an extra 100% of the amount of research and development expenses can be deducted before tax.

(c) Hong Kong profit tax

The Hong Kong profits tax rate of the subsidiary of the Group incorporated in Hong Kong is 16.5%.

(d) Profit/income tax rate in other major jurisdictions as shown below:

Countries	**Income/profits tax rate**
United States	27.67%-29.84%
Singapore	17%
Brazil	15% & 34%
Germany	Corporation tax standard rate: 15.83% Trade tax standard rate: 16.63%
France	25%
Australia	30%
Spain	25%

(e) Withholding tax

According to the relevant regulations of the CIT laws of Mainland China, when a foreign investment enterprise in Mainland China distributes dividends out of the profits earned from January 1, 2008 onwards to its investors in other countries and regions, such dividends are subject to withholding tax at a rate of 10%.

As at June 30, 2025, the retained earnings of the Group's PRC subsidiaries not yet remitted to holding companies incorporated outside the PRC, for which no deferred tax liability had been provided, were approximately USD136,059,000 (December 31, 2024: USD125,841,000). Such earnings are expected to be retained by the PRC subsidiaries for reinvestment purposes and would not be remitted to their overseas holding companies in the foreseeable future based on management's best estimates of the Group's overseas funding requirements.

11 EARNINGS PER SHARE

(a) Basic earnings per share

Basic earnings per share is calculated by dividing the profit attributable to owners of the Company by the weighted average number of ordinary shares outstanding during the six months ended June 30, 2025 and 2024.

	Six months ended June 30,	
	2025	2024
	(Unaudited)	(Unaudited) (Restated)
Profit attributable to owners of the Company (USD'000)	**14,643**	3,165
Weighted average number of ordinary shares outstanding	**168,825,984**	168,218,520
Basic earnings per share (in USD)	**0.09**	0.02

(b) Diluted earnings per share

Diluted earnings per share are calculated by adjusting the weighted average number of shares outstanding to assume conversion of all dilutive potential shares.

The Group has two categories of potential ordinary shares in the six months ended June 30, 2025, which were the restricted share units granted after IPO ("**the Post-IPO RSU Schemes**") (Note 20(a)) and the share options granted after IPO ("**the Post-IPO Share Option Scheme**") (Note 20(b)).

A calculation is done to determine the number of shares that could have been acquired at fair value (determined as the average market share price of the Company's shares during the period) based on the monetary value of the subscription rights attached to outstanding restricted share units and share options. The number of shares calculated as above is compared with the number of shares that would have been issued assuming the exercise of the share options and the vest of restricted share units.

	Six months ended June 30,	
	2025	2024
	(Unaudited)	(Unaudited) (Restated)
Profit attributable to owners of the Company (USD'000)	**14,643**	3,165
Weighted average number of ordinary shares in issue	**168,825,984**	168,218,520
Adjustments for unvested restricted share units and share options	**595,514**	663,251
Weighted average number of ordinary shares for diluted earnings per share	**169,421,498**	168,881,771
Diluted earnings per share (in USD)	**0.09**	0.02

12 PROPERTY, PLANT AND EQUIPMENT

	Buildings *USD'000*	Plant and machinery *USD'000*	Transportation equipment *USD'000*	Furniture, fixtures, equipment *USD'000*	Leasehold improvements *USD'000*	Construction in progress *USD'000*	Total *USD'000*
At January 1, 2025							
Cost	28,556	51,714	739	2,937	7,321	11,177	102,444
Accumulated depreciation	(3,902)	(16,511)	(341)	(1,487)	(4,908)	–	(27,149)
Closing net book amount	24,654	35,203	398	1,450	2,413	11,177	75,295
Six months ended June 30, 2025 (Unaudited)							
Opening net book amount	24,654	35,203	398	1,450	2,413	11,177	75,295
Additions	–	1,199	303	292	17	8,666	10,477
Transfers	8,217	5,268	–	310	800	(14,595)	–
Disposals	–	(861)	(55)	(15)	–	–	(931)
Depreciation	(701)	(3,354)	(57)	(269)	(764)	–	(5,145)
Impairment charge	–	(338)	–	–	–	–	(338)
Currency translation differences	335	625	50	33	421	483	1,947
Closing net book amount	32,505	37,742	639	1,801	2,887	5,731	81,305
At June 30, 2025 (Unaudited)							
Cost	37,127	57,739	1,055	3,561	8,634	5,731	113,847
Accumulated amortisation and impairment	(4,622)	(19,997)	(416)	(1,760)	(5,747)	–	(32,542)
Closing net book amount	32,505	37,742	639	1,801	2,887	5,731	81,305

	Buildings *USD'000*	Plant and machinery *USD'000*	Transportation equipment *USD'000*	Furniture, fixtures, equipment *USD'000*	Leasehold improvements *USD'000*	Construction in progress *USD'000*	Total *USD'000*
At January 1, 2024							
Cost	28,066	36,509	513	2,319	8,781	6,915	83,103
Accumulated depreciation	(2,596)	(12,628)	(354)	(1,111)	(5,866)	–	(22,555)
Closing net book amount	25,470	23,881	159	1,208	2,915	6,915	60,548
Six months ended June 30, 2024 (Unaudited) (Restated)							
Opening net book amount	25,470	23,881	159	1,208	2,915	6,915	60,548
Additions	–	1,727	370	154	51	11,622	13,924
Transfers	–	1,143	45	40	6,394	(7,622)	–
Disposals	–	(111)	–	(61)	–	–	(172)
Depreciation	(667)	(2,088)	(48)	(397)	(815)	–	(4,015)
Currency translation differences	(156)	(328)	(27)	(17)	(477)	(276)	(1,281)
Closing net book amount	24,647	24,224	499	927	8,068	10,639	69,004
At June 30, 2024 (Unaudited) (Restated)							
Cost	27,892	38,629	833	2,375	12,188	10,639	92,556
Accumulated depreciation	(3,245)	(14,405)	(334)	(1,448)	(4,120)	–	(23,552)
Closing net book amount	24,647	24,224	499	927	8,068	10,639	69,004

As at June 30, 2025 and December 31, 2024, the Group has pledged certain property, plants and equipment including CIP and plant and machinery in Brazil with a net carrying amount of Brazilian Real ("**BRL**") 29,068,000 (equivalent to approximately USD5,320,000) (2024: BRL11,377,000 (equivalent to approximately USD1,871,000)) for the banking facilities granted to a subsidiary of the Group to finance the subsidiary's daily working capital and capital expenditure plans.

Depreciation expenses were charged to the following categories in the interim condensed consolidated statement of comprehensive income:

	Six months ended June 30,	
	2025	2024
	USD'000	*USD'000*
	(Unaudited)	(Unaudited) (Restated)
Cost of revenue	**2,966**	1,856
Selling and marketing expenses	**533**	586
Administrative expenses	**1,343**	1,318
Research and development expenses	**303**	255
	5,145	4,015

13 INTANGIBLE ASSETS

	Goodwill *USD'000*	Software *USD'000*	Patents *USD'000*	Technology *USD'000*	Customer relationship *USD'000*	Brand *USD'000*	Total *USD'000*
At January 1, 2025							
Cost	**6,901**	**6,182**	**1,088**	**5,926**	**2,813**	**1,450**	**24,360**
Accumulated amortization	**–**	**(3,025)**	**(512)**	**(1,185)**	**(910)**	**(363)**	**(5,995)**
Closing net book amount	**6,901**	**3,157**	**576**	**4,741**	**1,903**	**1,087**	**18,365**
Six months ended June 30, 2025 (Unaudited)							
Opening net book amount	**6,901**	**3,157**	**576**	**4,741**	**1,903**	**1,087**	**18,365**
Additions	**–**	**531**	**–**	**–**	**–**	**–**	**531**
Amortization	**–**	**(436)**	**(53)**	**(315)**	**(241)**	**(124)**	**(1,169)**
Currency translation differences	**721**	**49**	**2**	**520**	**186**	**59**	**1,537**
Closing net book amount	**7,622**	**3,301**	**525**	**4,946**	**1,848**	**1,022**	**19,264**
At June 30, 2025 (Unaudited)							
Cost	**7,622**	**6,792**	**1,094**	**6,595**	**3,107**	**1,556**	**26,766**
Accumulated amortization	**–**	**(3,491)**	**(569)**	**(1,649)**	**(1,259)**	**(534)**	**(7,502)**
Closing net book amount	**7,622**	**3,301**	**525**	**4,946**	**1,848**	**1,022**	**19,264**

	Goodwill *USD'000*	Software *USD'000*	Patents *USD'000*	Technology *USD'000*	Customer relationship *USD'000*	Brand *USD'000*	Total *USD'000*
At January 1, 2024							
Cost	8,267	5,388	1,120	7,427	3,458	1,132	26,792
Accumulated amortization	–	(2,374)	(416)	(707)	(539)	(217)	(4,253)
Closing net book amount	8,267	3,014	704	6,720	2,919	915	22,539
Six months ended June 30, 2024 (Unaudited) (Restated)							
Opening net book amount	8,267	3,014	704	6,720	2,919	915	22,539
Additions	–	257	–	–	–	–	257
Amortization	–	(368)	(64)	(360)	(273)	(110)	(1,175)
Currency translation differences	(819)	(18)	(4)	(677)	(259)	(87)	(1,864)
Closing net book amount	7,448	2,885	636	5,683	2,387	718	19,757
At June 30, 2024 (Unaudited) (Restated)							
Cost	7,448	5,593	1,113	6,686	3,154	1,026	25,020
Accumulated amortization	–	(2,708)	(477)	(1,003)	(767)	(308)	(5,263)
Closing net book amount	7,448	2,885	636	5,683	2,387	718	19,757

	Six months ended June 30,	
	2025	2024
	USD'000	*USD'000*
	(Unaudited)	(Unaudited)
		(Restated)
Cost of revenue	**3**	5
Selling and marketing expenses	**75**	53
Administrative expenses	**1,004**	1,033
Research and development expenses	**87**	84
	1,169	1,175

14 RIGHT-OF-USE ASSETS

	Office premises *USD'000*	**Land use rights** *USD'000*	**Equipments** *USD'000*	**Total** *USD'000*
At January 1, 2025				
Cost	**11,524**	**8,265**	**4,721**	**24,510**
Accumulated depreciation	**(4,047)**	**(965)**	**(1,574)**	**(6,586)**
Net book amount	**7,477**	**7,300**	**3,147**	**17,924**
Six months ended June 30, 2025 (Unaudited)				
Opening net book amount	**7,477**	**7,300**	**3,147**	**17,924**
Additions	**2,519**	**–**	**–**	**2,519**
Depreciation	**(1,619)**	**(83)**	**(788)**	**(2,490)**
Currency translation differences	**353**	**31**	**11**	**395**
Closing net book amount	**8,730**	**7,248**	**2,370**	**18,348**
At June 30, 2025 (Unaudited)				
Cost	**14,281**	**8,300**	**4,741**	**27,322**
Accumulated depreciation	**(5,551)**	**(1,052)**	**(2,371)**	**(8,974)**
Net book amount	**8,730**	**7,248**	**2,370**	**18,348**

	Office premises *USD'000*	Land use rights *USD'000*	Equipments *USD'000*	Total *USD'000*
At January 1, 2024				
Cost	9,789	8,389	–	18,178
Accumulated depreciation	(3,355)	(812)	–	(4,167)
Net book amount	6,434	7,577	–	14,011
Six months ended June 30, 2024 (Unaudited) (Restated)				
Opening net book amount	6,434	7,577	–	14,011
Additions	571	–	4,777	5,348
Depreciation	(1,350)	(84)	(796)	(2,230)
Currency translation differences	(100)	(46)	(13)	(159)
Closing net book amount	5,555	7,447	3,968	16,970
At June 30, 2024 (Unaudited) (Restated)				
Cost	9,839	8,337	4,762	22,938
Accumulated depreciation	(4,284)	(890)	(794)	(5,968)
Net book amount	5,555	7,447	3,968	16,970

Depreciation expenses were charged to the following categories in the interim condensed consolidated statement of comprehensive income:

	Six months ended June 30,	
	2025	2024
	USD'000	*USD'000*
	(Unaudited)	(Unaudited) (Restated)
Cost of revenue	**1,494**	1,127
Selling and marketing expenses	**378**	431
Administrative expenses	**480**	528
Research and development expenses	**138**	144
	2,490	2,230

15 FINANCIAL INSTRUMENTS BY CATEGORY

	As at June 30, 2025 *USD'000* **(Unaudited)**	As at December 31, 2024 *USD'000* (Audited)
Financial assets		
Financial assets at amortized cost		
Cash and cash equivalents	**123,469**	227,103
Restricted cash	**109**	99
Term deposits with initial terms over three months	**247,650**	126,293
Trade and other receivables excluding non-financial assets	**44,322**	26,448
	415,550	379,943
Financial assets at FVPL	**180,763**	136,393
	596,313	516,336

	As at June 30, 2025 *USD'000* **(Unaudited)**	As at December 31, 2024 *USD'000* (Audited)
Financial liabilities		
Financial liabilities at amortized cost		
Other non-current financial liabilities	**41,148**	34,015
Trade and other payables excluding non-financial liabilities	**25,931**	25,809
Lease liabilities	**11,790**	11,135
Bank borrowings	**79,174**	3,348
	158,043	74,307

16 TRADE AND OTHER RECEIVABLES AND PREPAYMENTS

	As at June 30, 2025 *USD'000* (Unaudited)	As at December 31, 2024 *USD'000* (Audited)
Included in current assets		
Trade receivables *(Note (a))*		
– Due from third parties	**37,987**	17,979
– Due from related parties *(Note 26(c))*	**38**	282
	38,025	18,261
Less: allowance for impairment of trade receivables	**(5,041)**	(3,823)
	32,984	14,438
Other receivables		
– Receivables from payment platforms	**1,481**	590
– Deposits receivables	**2,183**	1,787
– Loans to third parties	**4,747**	4,706
– Others	**1,887**	1,967
	10,298	9,050
Less: allowance for impairment of other receivables	**(2,643)**	(788)
	7,655	8,262
Prepayments for		
– Taxes	**5,016**	5,405
– Suppliers	**8,159**	8,279
	13,175	13,684
	53,814	36,384
Included in non-current assets		
Trade receivables *(Note (a))*		
– Due from third parties	**174**	251
Less: allowance for impairment of trade receivables	**–**	(15)
	174	236

	As at June 30, 2025 USD'000 (Unaudited)	As at December 31, 2024 USD'000 (Audited)
Other receivables		
– Loans provided to employees	**3,540**	3,544
Less: allowance for impairment of other receivables	**(31)**	(32)
	3,509	3,512
Prepayments for		
– Suppliers	**4,798**	4,799
– Property, plant and equipment and other non-current assets	**7,368**	620
	12,166	5,419
	15,849	9,167

(a) Trade receivables mainly arise from rendering of clear aligner treatment solutions and sales of products. The Group generally received advances prior to the rendering of services or sales, while certain customers are mainly given a credit term of 30 to 90 days.

The following is an ageing analysis of trade receivables presented based on invoice dates:

	As at June 30, 2025 USD'000 (Unaudited)	As at December 31, 2024 USD'000 (Audited)
Within 1 year	**28,199**	13,284
1 to 2 years	**6,195**	2,037
2 to 3 years	**849**	289
Over 3 years	**2,956**	2,902
	38,199	18,512

The Group applies the simplified approach to provide for expected credit losses prescribed by IFRS 9.

The loss allowance provision as at June 30, 2025 and December 31, 2024 is determined as follows, the expected credit losses below also incorporate forward looking information.

	Within 1 year	1 to 2 years	2 to 3 years	Over 3 years	Total
At June 30, 2025 (Unaudited)					
Expected loss rates	**2.05%**	**10.35%**	**40.45%**	**100.00%**	
Gross carrying amount (USD'000)	**28,035**	**5,855**	**754**	**2,448**	**37,092**
Loss allowance provision (USD'000)	**(575)**	**(606)**	**(305)**	**(2,448)**	**(3,934)**
At December 31, 2024 (Audited)					
Expected loss rates	2.89%	12.52%	54.01%	100.00%	
Gross carrying amount (USD'000)	13,257	1,933	237	2,392	17,819
Loss allowance provision (USD'000)	(383)	(242)	(128)	(2,392)	(3,145)

The Group takes into account the changes in its customers' operating performance and future recoverability of trade receivables. The Group makes individual assessment on receivables when the counterparty fails to make repayment plan with the Group or becomes insolvency.

Trade receivables subject to individual provision

	As at June 30, 2025	As at December 31, 2024
	USD'000	*USD'000*
	(Unaudited)	(Audited)
Gross carrying amount	**1,107**	693
Loss allowance provision	**(1,107)**	(693)
Expected loss rate	**100%**	100%

The loss allowance provision for trade receivables as at June 30, 2025 and 2024 reconciles to the opening loss allowance for that provision as follows:

	Six months ended June 30,	
	2025	2024
	USD'000	*USD'000*
	(Unaudited)	(Unaudited)
		(Restated)
At the beginning of the period	**3,838**	4,604
Provision for loss allowance recognized in profit or loss	**1,168**	200
Currency translation differences	**35**	(33)
At the end of the period	**5,041**	4,771

As at December 31, 2024 the Group has pledged certain trade receivables in Brazil with a carrying amount of BRL13,734,000 (equivalent to approximately USD2,259,000) for the banking facilities granted to the subsidiary of the Group to finance the subsidiary's daily working capital and capital expenditure plans. As at June 30, 2025, no trade receivables are pledged.

17 CASH AND CASH EQUIVALENTS, TERM DEPOSITS AND RESTRICTED CASH

	As at June 30, 2025	As at December 31, 2024
	USD'000	*USD'000*
	(Unaudited)	(Audited)
Included in current assets		
Cash at banks	**123,462**	227,102
Cash on hand	**7**	1
Cash and cash equivalents	**123,469**	227,103
Term deposits with initial terms over three months	**220,736**	111,948
Restricted cash	**109**	99
Included in non-current assets		
Term deposits with initial terms over three months	**26,914**	14,345

18 FINANCIAL ASSETS AT FVPL

	As at June 30, 2025 *USD'000* (Unaudited)	As at December 31, 2024 *USD'000* (Audited)
Wealth management products with variable return *(Note a)*	**143,339**	97,778
Associate *(Note b)*	**2,281**	2,287
Other investees *(Note c)*	**35,143**	35,645
Derivative financial asset – Call option in a subsidiary *(Note d)*	**–**	683
	180,763	136,393

(a) Wealth management products with variable return

	As at June 30, 2025 *USD'000* (Unaudited)	As at December 31, 2024 *USD'000* (Audited)
Balance at the beginning of the year	**97,778**	106,018
Additions	**363,575**	597,401
Realized and unrealized fair value gains recognized in profit or loss	**2,601**	3,421
Disposals	**(320,565)**	(607,895)
Currency translation differences	**(50)**	(1,167)
Balance at the end of the period/year	**143,339**	97,778
– Included in current assets	**143,339**	97,778

(b) Associates

	As at June 30, 2025 *USD'000* (Unaudited)	As at December 31, 2024 *USD'000* (Audited)
Balance at the beginning of the year	**2,287**	–
Addition	**–**	2,112
Unrealized fair value (losses)/gains recognized in profit or loss	**(16)**	202
Currency translation differences	**10**	(27)
Balance at the end of the period/year	**2,281**	2,287
– Included in non-current assets	**2,281**	2,287

All investments in associates measured at fair value through profit or loss are in the form of convertible redeemable preferred instruments or ordinary shares with preferential rights.

(c) Other investees

	As at June 30, 2025 *USD'000* (Unaudited)	As at December 31, 2024 *USD'000* (Audited)
Balance at the beginning of the year	**35,645**	34,206
Additions	**4,000**	3,408
Unrealized fair value losses recognized in profit or loss	**(4,538)**	(1,865)
Currency translation differences	**36**	(104)
Balance at the end of the period/year	**35,143**	35,645
– Included in non-current assets	**35,143**	35,645

(d) Derivative financial asset – Call option in a subsidiary

	As at June 30, 2025 *USD'000* (Unaudited)	As at December 31, 2024 *USD'000* (Audited)
Balance at the beginning of the year	**683**	1,214
Unrealized fair value losses recognized in profit or loss	**(727)**	(322)
Currency translation differences	**44**	(209)
Balance at the end of the period/year	**–**	683
– Included in non-current assets	**–**	683

19 SHARE CAPITAL AND PREMIUM AND SHARES HELD FOR EMPLOYEE SHARE SCHEME

(a) Share capital and premium

	Number of ordinary shares	Nominal value of ordinary shares *USD* (Unaudited) (Restated)	Share capital *USD'000* (Unaudited) (Restated)	Share premium *USD'000* (Unaudited) (Restated)
At January 1, 2024	169,097,784	16,909	17	439,086
Shares issued for restricted share award scheme	142,580	14	*	–
Dividends	–	–	–	(23,837)
Repurchase and cancellation of shares	(19,400)	(2)	*	(130)
At June 30, 2024 (Unaudited)	169,220,964	16,921	17	415,119
At January 1, 2025	**170,025,325**	**17,003**	**17**	**415,426**
Shares issued for restricted share award scheme *(i)*	**736,920**	**74**	*	**–**
Dividends *(ii)*	**–**	**–**	**–**	**(8,315)**
At June 30, 2025 (Unaudited)	**170,762,245**	**17,077**	**17**	**407,111**

* The balance represents an amount less than USD1,000.

(i) On June 26, 2025, the Company issued and allotted 736,920 shares to Cultivate Happiness Limited (the "**Trustee**"), an entity held by a trustee entrusted by the Group for the purpose of the Post-IPO RSU Scheme (Note 20(a)(i)).

(ii) On May 23 2025, the Board recommended the payment of a special final dividend of Hong Kong dollar ("**HKD**") 0.38 per share (equivalent to approximately USD8,315,000) for the year ended December 31, 2024 out of the share premium account of the Company, which was approved by the shareholders of the Company at the annual general meeting held on May 23, 2025 and paid on June 17, 2025.

(b) Shares held for employee share scheme

	Six months ended June 30,	
	2025	2024
	USD'000	*USD'000*
	(Unaudited)	(Unaudited) (Restated)
Balance at the beginning of the period	*	*
Shares issued for restricted share award scheme *(Note 20(a)(i))*	*	*
Transfer of shares held for employee share scheme upon vesting	*	*
Balance at the end of the period	*	*

* The balance represents an amount less than USD1,000.

20 SHARE-BASED PAYMENTS

(a) The Post-IPO RSU Scheme

The Post-IPO RSU Scheme was conditionally approved and adopted by the Group on May 20, 2021 and amended on June 29, 2023 and June 28, 2024.

The number of restricted shares granted to the Group's eligible participants is summarized as follows:

	Number of restricted shares Six months ended June 30,	
	2025	2024
	(Unaudited)	(Unaudited)
Outstanding as at the beginning of the period	**1,008,639**	757,856
Granted *(i)*	**809,895**	142,580
Vested	**(55,226)**	(35,235)
Lapsed	**(19,058)**	(21,587)
Outstanding as at the end of the period	**1,744,250**	843,614

(i) Pursuant to the Post-IPO RSU Scheme, 72,975 shares were further granted to 50 eligible participants on March 21, 2025. The restricted share units will be vested based on the following schedule for the relevant financial year: (i) For 25,800 granted shares, 30%, 30%, 20% and 20% shall vest on the dates of September 30, 2025, 2026, 2027 and 2028, respectively. (ii) 47,175 RSUs granted shall vest in three tranches of 50%, 25% and 25% on the second, the third and the fourth anniversary of the hire date of the RSU Granted, respectively.

Pursuant to the Post-IPO RSU Scheme, 736,920 shares were further granted to 231 eligible participants on June 24, 2025. The restricted share units will be vested based on the following schedule for the relevant financial year: For 736,920 granted shares, 30%, 30%, 20% and 20% shall vest on the dates of September 30, 2025, 2026, 2027 and 2028, respectively.

The fair value of the restricted share units at grant date was determined with reference to the market price of the Company's shares on the respective grant dates.

During the six months ended June 30, 2025, the fair value of granted shares was USD6,011,000 for the Post-IPO RSU Scheme (six months ended June 30, 2024: USD1,369,000).

The outstanding restricted share as at June 30, 2025 were divided into three to seven tranches at their grant dates. The first tranche can be vested at a specified date or at the anniversary of the employment date of each grantee, and the remaining tranches will be vested in each subsequent year.

The Group has to estimate the expected percentage of eligible participants that will stay within the Group (the "**Expected Retention Rate**") of the restricted share award scheme in order to determine the amount of share-based payment expenses charged to the consolidated statements of comprehensive income. As at June 30, 2025, the Expected Retention Rate was assessed to be 92% (2024: 92%).

(b) The Post-IPO Share Option Scheme

The Post-IPO Share Option Scheme was conditionally approved and adopted by the Group on May 20, 2021 and amended on June 29, 2023 and January 28, 2024.

(i) Movements in the share options

Movements in the number of share options outstanding and their related weighted average exercise prices are as follows:

	Six months ended June 30,			
	2025		2024	
	Average exercise price HKD (Unaudited)	**Number of options (Unaudited)**	Average exercise price HKD (Unaudited)	Number of options (Unaudited)
Outstanding as at the beginning of the period	**93.55**	**3,056,396**	100.06	3,158,646
Granted *(I)*	**56.53**	**157,422**	79.00	827,750
Cancelled	**–**	**–**	100.06	(990,000)
Outstanding as at the end of the period	**91.73**	**3,213,818**	94.24	2,996,396
Exercisable as at the end of the period	**95.89**	**1,539,965**	100.06	789,662

(I) On January 17, 2025, the Board announces that to provide long-term motivation to key employees, the Company granted 34,590 options to one grantee with rights to subscribe for an aggregate of 34,590 shares upon exercise of such options in accordance with the terms of the Post-IPO Share Option Scheme, subject to acceptance of the option grantee.

On June 24, 2025, the Board announces that to provide long-term motivation to key employees, the Company granted 122,832 options to two grantees with rights to subscribe for an aggregate of 122,832 shares upon exercise of such options in accordance with the terms of the Post-IPO Share Option Scheme, subject to acceptance of the option grantee.

(ii) Outstanding in the share options

Details of the expiry dates, exercise prices and the respective numbers of share options which remained outstanding as at June 30, 2025 and December 31, 2024 are as follows:

Grante Date	**Expiry date**	**Exercise price**	**Number of share options**	
			As at June 30, 2025 (Unaudited)	As at December 31, 2024 (Audited)
April 28, 2023	April 28, 2033	HKD100.06	**2,168,646**	2,168,646
April 30, 2024	April 30, 2034	HKD79.00	**827,750**	827,750
July 17, 2024	July 17, 2034	HKD58.75	**60,000**	–
January 17, 2025	January 17, 2035	HKD52.55	**34,590**	–
June 24, 2025	June 24, 2035	HKD57.65	**122,832**	–
			3,213,818	2,996,396

The outstanding share options as at June 30, 2025 were divided into three to seven tranches at their grant dates. The first tranche can be exercised at a specified date and then the remaining tranches will become exercisable in each subsequent year.

(iii) Fair value of options

The Group uses the binomial option pricing model in determining the estimated fair value of the options granted, which was to be expensed over the relevant vesting period. The weighted average fair value of options granted during the six months ended June 30, 2025 was USD3.00 per share (six months ended June 30, 2024: USD4.36 per share).

Other than the exercise price mentioned above, the other significant inputs into the binomial valuation model were listed as below:

	Six months ended June 30,	
	2025	2024
	(Unaudited)	(Audited)
Weighted average share price at the grant date	**HKD56.44**	HKD79.00
Risk-free rate	**3.11%- 3.75%**	3.68%- 3.89%
Dividend yield	**1.05%**	1.00%
Expected volatility	**40.63%- 40.91%**	40.18%- 45.29%

(c) Share-based compensation expenses

The total share-based compensation expenses recognized are as follows:

	Six months ended June 30,	
	2025	2024
	USD'000	*USD'000*
	(Unaudited)	(Unaudited) (Restated)
Expenses arising from equity-settled share-based payment transactions	**4,361**	5,183

21 TRADE AND OTHER PAYABLES

	As at June 30, 2025	As at December 31, 2024
	USD'000	*USD'000*
	(Unaudited)	(Audited)
Trade payables *(Note (a))*	**11,746**	11,425
Employee benefits payable	**21,288**	26,919
Other taxes payable	**10,262**	9,944
Accrued expenses payable	**3,867**	4,585
Payables in relation with acquisition of property, plant and equipment	**4,251**	3,574
Deposits payable	**3,042**	3,078
Professional service fees payable	**1,396**	1,220
Advertising and promotion expenses payable	**1,146**	958
Provision for contingencies	**879**	760
Others	**483**	969
	58,360	63,432

(a) The credit period granted by suppliers mainly ranges from 30 to 60 days. The following is an ageing analysis of trade payables presented based on the invoice date:

	As at June 30, 2025 *USD'000* **(Unaudited)**	As at December 31, 2024 *USD'000* (Audited)
Within 1 year	**11,181**	10,911
Over 1 year	**565**	514
	11,746	11,425

(b) As at June 30, 2025 and December 31, 2024, trade and other payables of the Group were interest-free.

22 BANK BORROWINGS

	As at June 30, 2025 *USD'000* **(Unaudited)**	As at December 31, 2024 *USD'000* (Audited)
Included in current liabilities:		
Bank borrowing, unsecured	**76,092**	–
Bank borrowing, secured	**2,290**	2,860
Included in non-current liabilities:		
Bank borrowing, secured	**792**	488
	79,174	3,348

Assets pledged as security

The bank borrowings are secured by the Group's trade receivables and property, plants and equipment in Brazil. The carrying amounts of assets pledged as security for current and non-current borrowings were as follows:

	As at June 30, 2025 *USD'000* **(Unaudited)**	As at December 31, 2024 *USD'000* (Audited)
Current		
– Trade receivables	**–**	2,259
Non-current		
– Property, plant and equipment	**5,320**	1,871
Total assets pledged as security	**5,320**	4,130

At June 30, 2025, the Group's borrowings were repayable as follows:

	As at June 30, 2025 *USD'000* **(Unaudited)**	As at December 31, 2024 *USD'000* (Audited)
Within 1 year	**78,382**	2,860
Between 1 and 2 years	**423**	488
Between 2 and 5 years	**369**	–
	79,174	3,348

As at June 30, 2025, the Group's bank borrowings bear interests at fixed interest rates ranging from 1.6% to 7% (2024: 6% to 9%) per annum.

The Group has complied with all loan covenants (including financial and non-financial) throughout the reporting period.

23 OTHER NON-CURRENT LIABILITIES

	As at June 30, 2025 *USD'000* **(Unaudited)**	As at December 31, 2024 *USD'000* (Audited)
Measured at amortised cost:		
– Redemption liability *(Note (a))*	**41,148**	34,015
– Taxes payable	**271**	353
	41,419	34,368

(a) It mainly comprised redemption liability arising from put option arrangements with non-controlling shareholders of Aditek of approximately USD41,148,000 (December 31, 2024: USD34,015,000).

24 DIVIDENDS

The Board has resolved to declare the payment of a special interim dividend of HKD0.46 per share for the six months ended June 30, 2025 (six months ended June 30, 2024: nil).

25 COMMITMENTS

(a) Commitments relating to short-term leases

The Group has recognized right-of-use assets and lease liabilities for these leases, except for short-term leases, see Note 14 for further information.

The future aggregate minimum lease payments under non-cancellable short-term leases contracted for at the end of the period/year but not recognized as liabilities, are as follows:

	As at June 30, 2025 ***USD'000*** **(Unaudited)**	As at December 31, 2024 *USD'000* (Audited)
No later than 1 year	**162**	321

(b) Capital commitments

The Group's capital expenditure contracted for at the end of the period/year but not yet incurred is as follows:

	As at June 30, 2025 ***USD'000*** **(Unaudited)**	As at December 31, 2024 *USD'000* (Audited)
Property, plant and equipment	**2,095**	1,788
Intangible assets	**1,188**	521
	3,283	2,309

26 RELATED PARTY TRANSACTIONS

(a) Names and relationships with related parties

Below is the summary of the Group's related parties during the six months ended June 30, 2025:

Name of the related party	Relationship with the Group
Changsha Minjian Medical Equipment Co., Ltd. ("**Changsha Minjian**")	An entity significantly influenced by CareCapital Group
Chengdu Yafei Dental Co., Ltd. ("**Chengdu Yafei**")	An entity controlled by CareCapital Group
Dongguan Jianli Dental Hospital ("**Dongguan Jianli**")	An entity significantly influenced by CareCapital Group
Guangzhou Yilu Precision Medical Devices Co., Ltd. ("**Guangzhou Yilu**")	An entity controlled by CareCapital Group
Guiyang Jinxin Medical Instrument Co., Ltd. ("**Guiyang Jinxin**")	An entity controlled by CareCapital Group
Henan Red Sun Medical Instrument Co., Ltd. ("**Henan Red Sun**")	An entity controlled by CareCapital Group
Huizhou Dental Hospital Co., Ltd. ("**Huizhou Dental Hospital**")	An entity controlled by CareCapital Group
Huizhou Huiyang Huikou Dental Clinic Co., Ltd. ("**Huikou Dental Clinic**")	An entity controlled by CareCapital Group
Luoyang Smile Songbai Medical Equipment Co., Ltd. ("**Luoyang Smile**")	An entity controlled by CareCapital Group
Songbai Huaren (Shanxi) Medical Instrument Co., Ltd. ("**Songbai Huaren (Shanxi)**")	An entity controlled by CareCapital Group
Songbai Leye Medical Equipment (Ningbo) Co., Ltd. ("**Songbai Leye**")	An entity controlled by CareCapital Group
Songbai Maishi (Shanxi) Medical Instrument Co., Ltd. ("**Songbai Maishi (Shanxi)**")	An entity controlled by CareCapital Group
Songbai Oukang (Liaoning) Medical Instrument Co., Ltd. ("**Songbai Oukang (Liaoning)**")	An entity controlled by CareCapital Group
Songbai Qihai (Qingdao) Medical Instrument Co., Ltd. ("**Songbai Qihai (Qingdao)**")	An entity controlled by CareCapital Group
Taiyuan Yishunkang Medical Device Co., Ltd. ("**Yishunkang**")	An entity controlled by CareCapital Group
Zhengzhou Smile Songbai Industrial Co., Ltd. ("**Zhengzhou Smile**")	An entity controlled by CareCapital Group
Zhenjiang Wenjie Medical Equipment Co., Ltd. ("**Zhenjiang Wenjie**")	An entity controlled by CareCapital Group
Hemai Songmao (Shanxi) Medical Device Co., Ltd. ("**Hemai Songmao (Shanxi)**")	An entity controlled by CareCapital Group
Huizhou Huidong Huikou Dental Hospital Co., Ltd. ("**Huikou Dental Hospital**")	An entity controlled by CareCapital Group
Nogueira & Lopes Holding Ltda. ("**Nogueira**")	An entity controlled by Aditek's minority shareholders
Shanghai Chemrope New Material Technology Co., Ltd. ("**Shanghai Chemrope**")	An entity significantly influenced by CareCapital Group (An entity controlled by Shanghai Maxflex)
Shanghai Kaihao Technology Co., Ltd. ("**Shanghai Kaihao**")	An entity significantly influenced by Ms. LI Huamin, one of our substantial Shareholders (After March 26, 2025)
Shanghai Maxflex Medical Technology Co., Ltd. ("**Shanghai Maxflex**")	An entity significantly influenced by CareCapital Group
Songbai Oukang (Dalian) Medical Device Co., Ltd. ("**Songbai Oukang (Dalian)**")	An entity controlled by CareCapital Group
Astro Science do Brasil Pesquisa e Desenvolvimento S.A. ("**Astro Science**")	Joint venture held by the Group

(b) Transactions with related parties

During the six months ended June 30, 2025, save as disclosed elsewhere in this report, the following is a summary of the significant transactions carried out between the Group and its related parties.

	Six months ended June 30,	
	2025	2024
	USD'000	*USD'000*
	(Unaudited)	(Unaudited)
		(Restated)
Sales of clear aligner treatment solutions		
Guangzhou Yilu	**3,031**	2,916
Zhengzhou Smile	**2,113**	1,938
Songbai Oukang (Liaoning)	**1,104**	482
Zhenjiang Wenjie	**668**	528
Yishunkang	**525**	458
Songbai Maishi (Shanxi)	**188**	33
Songbai Leye	**175**	137
Changsha Minjian	**86**	78
Songbai Oukang (Dalian)	**52**	–
Hemai Songmao (Shanxi)	**50**	–
Songbai Qihai (Qingdao)	**29**	16
Guiyang Jinxin	**4**	12
Henan Red Sun	**3**	6
Luoyang Smile	**3**	13
Huikou Dental Clinic	**1**	–
Songbai Huaren (Shanxi)	**–**	1
	8,032	6,618
Sales of intraoral scanners		
Zhengzhou Smile	**131**	15
Songbai Oukang (Liaoning)	**48**	–
Guangzhou Yilu	**10**	5
Yishunkang	**8**	–
Zhenjiang Wenjie	**1**	–
Songbai Leye	**–**	1
	198	21
Purchase of raw materials and related services		
Shanghai Kaihao	**2,126**	–
Shanghai Maxflex	**794**	–
Astro Science	**246**	230
	3,166	230
Payment of property leases		
Nogueira	**105**	–

(c) **Outstanding balances arising from sales of goods and services**

	As at June 30, 2025 *USD'000* (Unaudited)	As at December 31, 2024 *USD'000* (Audited)
Trade and other receivables		
Guiyang Jinxin	**23**	54
Shanghai Kaihao	**8**	–
Chengdu Yafei	**7**	6
Guangzhou Yilu	**–**	87
Changsha Minjian	**–**	49
Zhengzhou Smile	**–**	29
Zhenjiang Wenjie	**–**	47
Songbai Leye	**–**	8
Songbai Oukang (Liaoning)	**–**	1
Yishunkang	**–**	1
	38	282

As at June 30, 2025 and December 31, 2024, the balances were with trade nature, unsecured, interest-free, and collectable on demand.

	As at June 30, 2025 *USD'000* (Unaudited)	As at December 31, 2024 *USD'000* (Audited)
Contract liabilities		
Guangzhou Yilu	**1,962**	1,858
Zhengzhou Smile	**1,953**	1,944
Yishunkang	**442**	457
Zhenjiang Wenjie	**407**	433
Songbai Oukang (Liaoning)	**402**	390
Songbai Leye	**97**	140
Songbai Maishi (Shanxi)	**68**	52
Changsha Minjian	**39**	–
Songbai Qihai (Qingdao)	**37**	27
Hemai Songmao (Shanxi)	**19**	–
Luoyang Smile	**10**	14
Songbai Oukang (Dalian)	**10**	–
Dongguan Jianli	**9**	–
Henan Red Sun	**6**	10
Huizhou Dental Hospital	**2**	–
Songbai Huaren (Shanxi)	**1**	–
	5,464	5,325

Contract liabilities of the Group mainly arose from the advance payments made by customers while the underlying goods or services are yet to be provided.

(d) Key management compensation

The Group's key management includes directors of the Company.

	Six months ended June 30,	
	2025	2024
	USD'000	*USD'000*
	(Unaudited)	(Unaudited)
		(Restated)
Fees	**140**	141
Salaries and wages	**1,043**	1,015
Bonuses	**525**	322
Share-based compensation expenses	**1,692**	2,458
Pension costs – defined contribution plans	**40**	25
Other social security costs, housing benefits and other employee benefits	**185**	117
	3,625	4,078

(e) Outstanding balances arising from purchase of raw materials

	As at June 30, 2025	As at December 31, 2024
	USD'000	*USD'000*
	(Unaudited)	(Audited)
Trade and other payable		
Shanghai Kaihao	**1,144**	–
Shanghai Maxflex	**194**	–
Astro Science	**71**	64
	1,409	64

(f) Outstanding balances arising from loans provided to key management

	As at June 30, 2025	As at December 31, 2024
	USD'000	*USD'000*
	(Unaudited)	(Audited)
Loans provided to key management		
Balance at the beginning of the year	**2,596**	2,758
Proceeds of loans repaid by key management	**–**	(194)
Interests incurred	**53**	94
Currency translation differences	**11**	(62)
Balance at the end of the period/year	**2,660**	2,596

27 CONTINGENT LIABILITIES

The Group did not have any material contingent liabilities as at June 30, 2025.

28 SUBSEQUENT EVENTS

Details of the interim dividend proposed are given in Note 24.

OTHER INFORMATION

Use of Proceeds

The ordinary shares of the Company (the "**Shares**") were listed on the Main Board of the Stock Exchange on June 16, 2021, whereby 16,829,600 new Shares were issued at the offer price of HKD173.0 each by the Company. On July 8, 2021, the Joint Global Coordinators, on behalf of the International Underwriters, fully exercised the Over-allotment Option at the offer price of HKD173.0, pursuant to which the Company issued an addition of 2,524,400 Shares. The aggregate net proceeds from the Company's Global Offering, including the net proceeds from the full exercise of the Over-allotment Option and after deduction of the underwriting fees and other related expenses, was approximately HKD3,139.0 million. The net proceeds from the Global Offering (adjusted on a pro rata basis based on the actual net proceeds) have been and will be utilized in that same manner, proportion and the expected timeframe as set out in the Prospectus under the section headed "Future Plans and Use of Proceeds". The table below sets out the planned and actual applications of the net proceeds as at June 30, 2025.

	Net proceeds from the Global Offering	Unutilized proceeds as at December 31, 2024	Utilized proceeds during the Reporting Period	Utilized proceeds as at June 30, 2025	Unutilized proceeds as at June 30, 2025
			(HKD in millions)		
Funding the construction of Chuangmei Center	1,252.5	666.9	41.5	627.1	625.4
Strengthening our research and development capabilities and funding our in-house and collaborative R&D initiatives	574.4	128.0	73.5	519.9	54.5
Developing a flexible and scalable intelligent information technology system	339.0	106.9	46.0	278.1	60.9
Expanding our in-house sales team and providing sales personnel with training sessions	329.6	0.0	0.0	329.6	0.00
Funding marketing and branding activities	301.4	0.0	0.0	301.4	0.00
Optimizing medical services	194.6	0.0	0.0	194.6	0.00
Working capital and other general corporate purposes	147.5	0.0	0.0	147.5	0.00
Total	**3,139.0**	**901.8**	**161.0**	**2,398.2**	**740.8**

To the extent that the net proceeds have not been immediately utilized, the balance has been placed with banks. There has been no change in the intended use of net proceeds as previously disclosed in the Prospectus and the Group will apply the remaining net proceeds in the manner set out in the Prospectus. However, additional time will be required to utilize the remaining proceeds due to the impact of the macroeconomy in the past few years. Considering the needs of future development of the Group, we expect the remaining proceeds would be used by the end of 2026.

Employees, Training and Remuneration Policies

As at June 30, 2025, we had 3,542 employees. The staff costs including Directors' emoluments and share-based payment expenses were USD76.9 million in the six months period ended June 30, 2025.

Our employees' compensation includes basic salary, performance-based cash bonuses, incentive shares and other incentives. We determine our employees' compensation based on each employee's performance, qualifications, position and seniority.

We recognize the importance of keeping the Directors updated with the latest information of duties and obligations of a director of a company whose shares are listed on the Stock Exchange and the general regulatory and environmental requirements for such listed company. To meet this goal, we are committed to the continuing education and development of the Directors.

The Directors and senior management receive remuneration from the Company in the form of fees, salaries, contributions to pension schemes, discretionary bonuses, allowances and other benefits in kind. The Board has established the remuneration committee (the "**Remuneration Committee**") to review and recommend the remuneration and compensation packages of the Directors and senior management of the Company, and the Board, with the advice from the Remuneration Committee, will review and determine the remuneration and compensation packages taking into account salaries paid by comparable companies, time commitment and responsibilities of the Directors and senior management and performance of the Group.

In accordance with the labour laws and regulations in mainland China and other countries and regions we operate in, our local corporate entities have respectively established labour relationships with the local employees and, where applicable, entered into labour contracts covering matters such as wages, bonuses, employee benefits, workplace safety, confidentiality obligations, non-competition obligations and reasons for termination.

To incentivize its employees and promote the long-term growth of the Company, we have also conditionally adopted several share award schemes to provide equity incentive to the Group's employees, directors and senior management.

We provide pre-employment and regular continuing management and technical training to our employees, which we believe are effective in equipping them with the skill set and work ethics that we require.

We believe that we have maintained a good working relationship with our employees and we had not experienced any material labor disputes or any difficulty in recruiting staff for our operations during the Reporting Period.

Purchase, Sale or Redemption of the Company's Listed Securities

Neither the Company nor any of its subsidiaries had purchased, sold or redeemed any of the Company's listed securities, including sales of treasury shares as defined in the Listing Rules, during the Reporting Period. As at the end of the Reporting Period, the Company did not hold any treasury shares as defined in the Listing Rules.

Interim Dividend

The Board has resolved to declare the payment of a special interim dividend of HKD0.46 per share for the six months period ended June 30, 2025 to the Shareholders whose names appeared on the register of members of the Company on Friday, September 10, 2025, being the record date for determining Shareholders' entitlement to the special interim dividend (for the six months period ended June 30, 2024: nil). The proposed special interim dividend is expected to be paid on Tuesday, September 30, 2025.

Public Float

According to the information that is publicly available to the Company and within the knowledge of the Board, as at the date of this announcement, the Company has maintained to comply with the minimum percentage prescribed in the conditions imposed in the waiver granted by the Stock Exchange from strict compliance with Rule 8.08(1) of the Listing Rules.

Compliance with Corporate Governance Code

The Group is committed to maintaining high standards of corporate governance practices. The Board believes that good corporate governance standards are essential in providing a framework for the Company to safeguard the interests of the shareholders of the Company (the "**Shareholders**") and corporate value, formulate its business strategies and policies, and enhance its transparency and accountability.

The Company has adopted the principles and code provisions set out in the Corporate Governance Code (the "**CG Code**") under Appendix C1 of the Listing Rules as its own code of corporate governance. During the Reporting Period, the Company has complied with all applicable code provisions under the CG Code.

Compliance with the Model Code

The Company has adopted the Model Code for Securities Transactions by Directors of Listed Issuer (the "**Model Code**") set out in Appendix C3 to the Listing Rules as its code of conduct regarding Directors' securities transactions.

Having made specific enquiries of all Directors, each of the Directors has confirmed that he/she has complied with the requirements of the Model Code during the Reporting Period.

Audit Committee and Review of Interim Financial Results

As at the date of this announcement, the Audit Committee comprises three independent non-executive Directors, namely, Mr. ZHOU Hao, Mr. HAN Xiaojing and Mr. SHI Zi, and Mr. ZHOU Hao serves as the chairman of the Audit Committee.

The Audit Committee has reviewed the unaudited interim condensed consolidated financial information of the Group for the six months period ended June 30, 2025. The Audit Committee has also reviewed the accounting policies and practices adopted by the Company and discussed matters in relation to, among others, risk management, internal control and financial reporting of the Group with the management and PricewaterhouseCoopers, the independent auditor of the Company. Based on this review and discussions with the management and the independent auditor of the Company, the Audit Committee was satisfied that the Group's unaudited interim condensed consolidated financial information were prepared in accordance with applicable accounting standards and fairly presented the Group's financial position and results for the six months period ended June 30, 2025.

PricewaterhouseCoopers, certified public accountants and the independent auditor of the Company, has reviewed the unaudited interim condensed consolidated financial information of the Group for the six months period ended June 30, 2025 in accordance with International Standard on Review Engagements 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity."

Closure of Register of Members

For determining the entitlement of Shareholders to receive the special interim dividend, the register of members of the Company will be closed from Monday, September 8, 2025 to Wednesday, September 10, 2025, both days inclusive, during which period no transfer of Shares will be registered. To qualify for the proposed special interim dividend, all share transfer documents accompanied by the corresponding share certificates must be lodged with the Company's branch share registrar in Hong Kong, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong for registration not later than 4:30 p.m. (Hong Kong time) on Friday, September 5, 2025.

Events after the Reporting Period

As at the date of this announcement, save as disclosed in this announcement, there has been no significant event since the end of the Reporting Period that is required to be disclosed by the Company.

PUBLICATION OF 2025 INTERIM RESULTS AND 2025 INTERIM REPORT

This announcement is published on the websites of the Stock Exchange (**www.hkexnews.hk**) and the Company (**www.angelalign.com**). The interim report of the Company for the six months period ended June 30, 2025 will be dispatched to the Shareholders, if necessary, and published on the aforesaid websites in due course.

APPRECIATION

On behalf of the Board, I would like to express our sincere gratitude to dental professionals, patients and business partners for their trust in the Company, our staff and management team for their diligence, dedication, loyalty and integrity, and our Shareholders for their continuous support.

By order of the Board of Directors
Angelalign Technology Inc.
Mr. FENG Dai
Chairman

Hong Kong, August 25, 2025

As at the date of this announcement, the Board comprises Mr. HU Jiezhang, Mr. HUANG Kun, Mr. SONG Xin and Ms. DONG Li as executive Directors; Mr. FENG Dai as a non-executive Director; Mr. HAN Xiaojing, Mr. SHI Zi and Mr. ZHOU Hao as independent non-executive Directors.